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1. INTRODUCTION 
Endometriosis is a frequent chronic gynaecological disease affecting not only 
women’s health but also their life quality. Although endometriosis has been 
extensively studied for decades, the pathogenesis of the disease has remained 
enigmatic and the pathophysiology behind the development of endometriotic 
lesions is still largely unknown. Besides unknown pathogenesis, the diagnosis 
of endometriosis still depends on the findings from laparoscopic surgery as 
there are no non-invasive biomarkers with acceptable sensitivity and specificity 
enabling correct diagnostics. The search for potential biomarkers relies on the 
results of basic science research and thus, the molecular studies in endo-
metriotic lesions and endometria are fundamentally important to understand the 
disease pathogenesis and to find new biomarkers for diagnostic purposes.  
Why endometriosis develops and what are the molecular events triggering 
the implantation of endometrial cells into the ectopic locations, are the main 
questions any endometriosis researcher is faced with. The involvement of 
genetic factors in disease pathogenesis has been proposed and extensive effort 
has been made to reveal genetic background of the disease and to find possible 
molecular alterations responsible for disease development. Although the results 
of candidate gene association studies have not been very successful, the fast 
development of advanced and high-throughput technologies has opened new 
possibilities to get deeper insight into genetic, transcriptomic and epigenetic 
architecture of endometriotic lesions and endometria of endometriosis patients. 
To date, already more than 50 comprehensive profiling studies searching for 
molecular alterations in endometriotic lesions and eutopic endometria of 
endometriosis patients have been conducted and hundreds of potential markers 
have been proposed. However, the concordance between the results of these 
studies has remained moderate and new concerns have emerged. The concern 
about proper study design has been lately raised and the guidelines helping to 
harmonize endometriosis studies have been established. The relevance of study 
design in endometriosis research cannot be underestimated and all interfering 
factors (e.g. the composition and location of examined tissues and the effect of 
menstrual cycle on molecular processes) should be considered if conducting 
molecular profiling studies.  
The general aim of the current thesis was to use comprehensive molecular 
tools to assess genetic, transcriptomic and epigenetic profiles of eu- and ectopic 
endometrial tissues and thereby to discover molecular events accompanying 
endometriosis development.  
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2. REVIEW OF LITERATURE 
2.1. Endometriosis epidemiology 
Endometriosis is a common estrogen-dependent benign gynaecological disease 
affecting 5–10% of women of reproductive age and up to 50% of women with 
pelvic pain and infertility (Giudice, 2010). The exact prevalence of endo-
metriosis in Estonia is unknown but on average 300 women (0.1% of re-
productive-aged women) get the diagnosis of endometriosis every year (data 
from Estonian Health Insurance Fund and Statistics Estonia, January 2016). 
Endometriosis is characterized by the growth of functional endometrial tissue 
outside the uterine cavity. The cells growing in ectopic locations are under the 
influence of female hormones and follow the normal menstrual cycle, similarly 
to endometrial cells inside the uterus. During menstruation, the bleeding from 
desquamated ectopic lesions causes inflammatory processes inside the 
peritoneal cavity leading to the formation of adhesions and causing pain and 
infertility. The most common symptom of endometriosis is chronic or cyclic 
pain (pelvic pain, pain during menstruation and ovulation, painful sexual 
intercourse) and thus endometriosis has a huge impact on the quality of life of 
these women (Dunselman et al., 2014). In addition to pain symptoms, endo-
metriosis has also a major impact on women’s fertility, as it affects the ovarian 
reserve, causes poor oocyte and embryo quality and low implantation rates; 
however, the mechanisms behind endometriosis-associated infertility are still 
poorly understood (reviewed in Macer et al., 2012).  
The symptoms of endometriosis are nonspecific and it is proposed that the 
disease is underdiagnosed with an average delay of 7 years between the onset of 
the symptoms and the correct diagnosis (Rogers et al., 2013). The delay of the 
diagnosis can be explained by the fact that despite of extensive research, there 
are still no non-invasive diagnostic markers for endometriosis and according to 
the guidelines of European Society of Human Reproduction and Embryology 
(Dunselman et al., 2014) the gold standard for accurate diagnosis of endo-
metriosis is still laparoscopy together with histological verification of endo-
metrial glands and/or stromal cells of biopsied samples. The non-invasive 
imaging technologies like magnetic resonance imaging and transvaginal 
ultrasound can be used for diagnosing large endometriomas and deep endo-
metriotic nodules, though for accurate diagnosis (to determine severity of the 
disease, presence of adhesions, small endometriomas and superficial lesions) 
and for surgical treatment, laparoscopic surgery is still needed. Due to the 
invasive nature of endometriosis diagnostics, robust and specific non-invasive 
biomarkers with acceptable sensitivity and specificity, and detectable preferably 
from easily assessable sources like blood and body fluids, are needed. Although 
endometriosis biomarkers have been sought from peripheral blood (whole 
blood, plasma, serum), menstrual blood, peritoneal fluid and urine samples and 
more than 100 markers, among them annexin V, CA-125, glycodelin, glyco-
proteins, inflammatory and non-inflammatory cytokines, angiogenic and growth 
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factors have been assessed, the results of these studies have been inconsistent 
and have not provided diagnostic tests with sufficient predictive power (May et 
al., 2010; Vodolazkaia et al., 2012).  
The severity of endometriosis is classified into four stages (I-minimal, II-mild, 
III-moderate, and IV-severe) depending on the location, extent and depth of 
lesions, presence and extent of adhesions and endometriomas (ASRM, 1997). 
Women with minimal-mild (stage I–II) disease have superficial lesions and 
mild adhesions, women with moderate-severe endometriosis (stages III–IV) 
have usually superficial/deep infiltrating endometriosis (DIE) or endometriomas 
and severe adhesions. Curiously, the symptoms of endometriosis and severity of 
the disease correlate poorly with fertility outcome, severity of the pain or 
characteristics of lesions (type, size and location), making the diagnosis and 
research to reveal disease pathogenesis even more complicated. 
Although epidemiologic studies have found several risk factors for 
endometriosis such as menstrual cycle characteristics (early age at menarche, 
short menstrual cycles and heavy bleeding), taller height, decreased body mass 
index (BMI) and low number of pregnancies (reviewed in Cramer et al., 2002) 
the questions “why endometriosis develops, how endometrial cells reach to 
ectopic sites and how to find biomarkers for non-invasive diagnostics” have 
remained the main initiators for many basic science studies that will be 
summarized in the following sections. 
 
2.2. Endometriotic lesions morphology and histology 
As the location and general appearance of endometriotic lesions (such as colour, 
size and morphology) are highly variable between patients (Hsu et al., 2010), 
histological evaluation of biopsied lesions is needed to confirm the diagnosis of 
endometriosis and to facilitate optimal treatment. The most common locations 
of lesions are on the surface of pelvic cavity organs (ovaries, uterus and 
fallopian tubes), ligaments (uterosacral ligaments, broad and round ligaments), 
recto-uterine pouch and ovarian fossa. Extra-pelvic locations of lesions are rare 
but in some cases lesions can be found in upper abdomen, diaphragm but also 
on operation scars, urinary tract, bowel, appendix and rectum. Endometriotic 
lesions (Figure 1) can be divided into three different subtypes: firstly, super-
ficial peritoneal lesions which may be black, dark-brown, blue “powder-burn”, 
red, clear lesions or white areas of fibrosis, located mainly in pelvic peritoneal 
tissue and organs. Secondly, endometriomas that are ovarian cysts lined by 
endometrial tissue and filled with old dark-brown blood; and thirdly, DIE, in 
which case the endometrial cells penetrate > 5 mm into the adjacent fibro-
muscular tissue (reviewed in Hsu et al., 2010). It has been proposed that colour 
of the endometriotic lesions changes over time, starting from red, progressing to 
black and finally reaching the fibrotic white lesions (Nisolle et al., 1997). 
Different subtypes of endometriotic lesions can be found in combination, or just 
a single subtype can be present. To date, it is unclear whether different lesion 
subtypes share common pathologic mechanisms (Nisolle et al., 1997).  
12 
 
Figure 1. Photographs of endometriotic lesions. A. Peritoneal superficial endometriotic 
lesions on the Ligamentum sacrouterina. B. Endometriotic lesions on the surface of the 
ovarian mucinous cystadenoma. Photographs made by Dr. Pille Soplepmann (Tartu 
University Hospital, Estonia). 
 
The histological diagnosis of endometriosis requires the presence of at least two 
histological features in the lesion: either endometrial epithelial cells, endo-
metrial stromal cells surrounding the glandular epithelial cells or hemosiderin-
laden macrophages (Anaf et al., 2000) (Figure 2). During the routine histo-
logical assessment, several tissue sections from different parts of the biopsy are 
examined but identification of specific cells may still be complicated as many 
lesions with “typical” macroscopic appearance cannot be confirmed at the 
microscopic level (Moen et al., 1992; Walter et al., 2001). Although histo-
logical evaluation of lesions is routinely used in everyday practice, as many as 
30–50% of surgical specimens removed during laparoscopy are not confirmed 
by histological assessments (Moen et al., 1992; Stratton et al., 2003; Stegmann 
et al., 2008; Fernando et al., 2013). In endometriomas, the histopathological 
validation is even more variable ranging from 0% (Fayez et al., 1991) to 100% 
(Muzii et al., 2007). The possible reasons why histological assessment of the 
lesions may fail are inadequate sample collection during the laparoscopy, 
presence of lesion-like tissue structures in abdominal cavity, very small size of 
lesions or because samples may lack endometriotic glands, and sparse stromal 
cells may be hidden in surrounding tissue (Kennedy et al., 2005). The most 
common histopathologic findings of lesion-like structures include fibrosis, 
hemorrhagic changes, inflammatory changes and normal peritoneal tissue 
(Wanyonyi et al., 2011) and for endometrioma-like cysts, ovarian tissue, non-
diagnostic cysts and corpus luteum or albicans cysts are the usual findings 
(reviewed in Muzii et al., 2007).  
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Figure 2. Photomicrograph of peritoneal endometriotic lesion. Section of Ligamentum 
sacrouterina, 10 × magnification, 10 µm section stained with hematoxylin and eosin. 
Arrows indicate endometrial stromal and epithelial cells and adjacent healthy peritoneal 
tissue. 
 
 
2.3. Pathogenesis of endometriosis 
Despite of the extensive studies, the pathogenesis of the endometriosis has 
remained a mystery and there are several theories as to how endometrial cells 
reach to ectopic sites and which factors trigger the ectopic growth of the cells 
(Figure 3). The most popular Sampson’s retrograde menstruation theory 
postulates that endometrial cells are transported together with menstrual blood 
into the peritoneal cavity (Sampson, 1927). The coelomic metaplasia theory 
says that endometriosis arises from specialised cells from mesothelial lining of 
the visceral and abdominal peritoneal tissue, while the lympho-vascular 
metastasis theory hypothesizes that endometrial cells spread with lymphatic or 
hematologic flow. The theory of embryonic Müllerian rests proposes that cells 
of the Wolffian or Müllerian ducts maintain capacity to develop into lesions, 
whereas stem cell theory claims that extrauterine stem cells may differentiate 
into endometriotic tissue. The theory of peritoneal origin postulates that 
alterations in peritoneal mesothelial cells facilitate the binding and invasion of 
cells in extracellular matrix (Sasson et al., 2008; Burney et al., 2012; Young et 
al., 2013). Most recent theories of fetal origin of endometriosis and tissue post-
traumatic theory suggest that endometriosis may develop during the early 
embryogenesis in response to molecular alterations that lead to disruption of the 
fine-tuning mechanisms responsible for the correct development of the female 
genital system (Signorile et al., 2010a) or small microtrauma events could be 
the initial events triggering the disease development (Canis et al., 2016). Also, 
the involvement of environmental factors like dioxin, endocrine system 
5 
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modifications, oxidative stress and inflammation, inefficient clearance from 
menstrual debris in peritoneal cavity caused by immune or inflammatory 
deficiency, alterations in cell fate and apoptosis systems and genetic/epigenetic 
factors or a combination of these mechanisms in disease pathogenesis have been 
proposed (reviewed in Burney et al., 2012). 
 
 
Figure 3. The main theories of endometriosis development. 
 
Although there are many theories, no single theory can explain all aspects of the 
disease development. The most widely accepted Sampson’s retrograde men-
struation theory is supported by multiple lines of evidence, such as the presence 
of viable endometrial cells in menstrual and peritoneal fluid (Koninckx et al., 
1998), development of endometriotic lesions in non-human primates after 
inoculation of endometrial tissue into peritoneal cavity (D’Hooghe et al., 1991) 
and higher frequency of endometriosis in women with congenital abnormalities 
causing obstruction of outflow (Sanfilippo et al., 1986). However, retrograde 
menstruation is a universal phenomenon among healthy women with patent 
fallopian tubes and therefore this theory does not explain why endometriosis is 
present in only 5–10% of women. Why endometrial cells, irrespective of the 
mechanisms how they reach to the peritoneal cavity, are able to attach, invade 
and form ectopic endometrial lesions in some women is currently unknown, but 
the endometrial origin of endometriotic cells is widely accepted. Furthermore, it 
has been proposed that genomic, transcriptomic and epigenomic alterations in 
endometrial cells of some women could be responsible for the elevated ability 
of these cells to attach and grow in ectopic locations.  
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2.4. Molecular profiling studies in endometriotic  
lesions and endometria  
The advancements in genome-wide microarray and sequencing technologies 
started the molecular profiling (omics) era in endometriosis studies that has 
revolutionized our understanding about the disease background. Since 1999, 
around 50 publications using high throughput technologies and focusing on 
genomics, epigenomics and transcriptomics of endometriotic lesions and 
endometrium have been published (Figure 4).  
 
 
Figure 4. Molecular profiling studies in endometriosis. X-axis denotes the type of 
‘omicsʼ analysed, while Y-axis indicates the number of studies. The numbers above the 
bars indicate the numbers of the studies. “Lesion” indicates studies using either lesions 
or lesions together with endometrium, while “endometrium” indicates those studies 
using only endometria. Literature search was performed in PubMed, including studies 
published up to January 2016. Only publications in English were considered. The 
keyword ‘endometriosis’ was one-by-one searched in combination with terms: ‘endo-
metriumʼ, ‘miRNA+microarrayʼ, ‘sequencingʼ, ‘microarrayʼ, ‘gene expression+micro-
arrayʼ, ‘exome sequencingʼ, ‘GWASʼ, ‘CNVʼ, ‘genomicsʼ, ‘DNA methylationʼ, ‘DNA 
alterationsʼ. Some of the eligible studies were identified using the reference lists of 
appropriate review articles. Epigenome studies include only papers describing DNA 
methylation. 
 
Genomics is defined herein as variability in DNA sequence at the genome level, 
epigenomics as epigenetic modifications of DNA, and transcriptomics as 
variability in composition and abundance of mRNA and microRNA (miRNA) 
levels (Altmae et al., 2014). The major advantage of using molecular profiling 
when studying complex diseases with unknown pathogenesis such as 
endometriosis, is that the data can be collected without existing hypotheses and 
a primary research question is not always needed (first experiment-then-hypo-
thesize approach) (Ozdemir et al., 2009). Although the amount of molecular 
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profiling studies in endometriosis is still moderate, the number of studies is 
constantly growing because of the accessibility and affordability of new 
methods. A detailed review of ʼomicsʼ-level studies in endometriosis is given in 
the following chapters. 
 
 
2.4.1. Genomics of endometriosis 
2.4.1.1. Single nucleotide polymorphisms in endometriosis 
Endometriosis is a polygenic complex disease, which means its pathogenesis is 
affected by many different gene variants together with environmental influences. 
Comprehensive genome-wide association studies (GWAS) comprising thou-
sands of individuals and including hundreds of thousands single nucleotide 
polymorphisms (SNPs) together with further replication studies (Adachi et al., 
2010; Uno et al., 2010; Painter et al., 2011; Nyholt et al., 2012; Albertsen et al., 
2013; Pagliardini et al., 2013; Sundqvist et al., 2013; Sapkota et al., 2015) have 
been performed to elucidate the genetic predisposition to endometriosis. A 
recent meta-analysis included more than 11,506 patients and 32,678 controls 
and found that six loci were genome-wide significant, including rs12700667 on 
7p15.2, rs7521902 near WNT4, rs10859871 near VEZT, rs1537377 near 
CDKN2B-AS1, rs7739264 near ID4 and rs13394619 in GREB1 (Table 1) 
(Rahmioglu et al., 2014b). 
 
Table 1. Results of the GWAS metaanalysis (Rahmigiolu et al. 2014) 
SNP OR (95% CI)* P value Nearest gene 
rs7521902 1.18 (1.13–1.23) 1.8 × 10–15 WNT4 
rs12700667 1.13 (1.08–1.17) 1.9 × 10–9 intergenic 
rs1537377 1.12 (1.08–1.17) 1.0 × 10–8 CDKN2B-AS1 
rs10859871 1.18 (1.13–1.22) 4.8 × 10–15 VEZT 
rs7739264 1.11 (1.08–1.15) 1.8 × 10–10 ID4 
rs13394619 1.13 (1.07–1.20) 4.5 × 10–8 GREB1 
*OR, odds ratio, CI confidence interval 
 
Although GWAS have provided valuable information about SNPs and reported 
novel candidate genes as well as genome regions, the effect sizes for the asso-
ciated variants are quite moderate (odds ratios between 1.0–1.2). It is very likely 
that instead of common variants the rarer variants (minor allele frequency of 
<0.05) not captured by the GWAS genotyping arrays used in endometriosis 
studies thus far, could contribute to the risk of the disease (Visscher et al., 
2012).  
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2.4.1.2. Inherited DNA copy number variations in endometriosis 
Besides finding the involved gene variants and genes, genomic studies enable 
searching for inherited DNA copy number variations (CNVs). High-resolution 
SNP arrays, together with comparative genomic hybridization (CGH) and array-
CGH (aCGH) provide the opportunity to assess inherited and sporadic CNVs 
that may potentially contribute to development of many diseases, including 
endometriosis. Inherited CNVs, present in all cells of the human body, are 
relative small deletions or duplications of genomic segments that change the 
copy-number status of the specific genomic regions covering up to 13% of 
human genome (Stankiewicz et al., 2010). The loss or gain of specific genomic 
regions can lead to alterations in gene expression and it has been proposed that 
approximately 18% of gene expression variability comes from the presence of 
CNVs (Stranger et al., 2007). To date, there are more than three million CNVs 
(range from 100 bp to several Mb in size) reported in the database of genomic 
variants (DGV). Although many disease-related CNVs have been described (in 
association with hypertension, rheumatoid arthritis, type 1 diabetes, autism, 
breast cancer, obesity, Alzheimer disease etc.), large population-based CNV 
studies have found substantial variability in CNV distribution also in healthy 
individuals (Sebat et al., 2004; Pinto et al., 2007; Teo et al., 2011; Li et al., 
2013).  
Only one large-scale study for genomic CNVs from saliva samples in endo-
metriosis has been conducted (Chettier et al., 2014). This case-control study 
compared 2,126 surgically confirmed endometriosis cases to 17,974 controls 
and found that there were no significant differences neither in CNV counts, nor 
in proportion of large CNVs or gene-based CNVs between controls and patients 
(Chettier et al., 2014). Although this study failed to find any large CNVs that 
contribute to the pathogenesis of endometriosis, the analysis revealed 22 rare 
CNVs that were detected in 6.9% of affected women compared to 2.1% of the 
general population. Three out of 22 CNVs passed a genome-wide P-value 
threshold, namely a deletion at SGCZ on 8p22, a deletion in MALRD1 on 
10p12.31, and a deletion at 11q14.1 (Chettier et al., 2014). Although little is 
known about the function of MALRD1 and the CNV at 11q14.1 located in gene 
desert, the deletion of SGCZ (member of the sarcoglycan gene-family) that is a 
component of the vascular smooth muscle sarcoglycan complex could be 
involved in endometriosis pathogenesis as smooth muscle structures have been 
found in endometriotic lesions (Barcena de Arellano et al., 2014). As these 
CNVs have not been previously associated with endometriosis, further repli-
cation studies in different populations are needed to confirm the findings. 
 
 
2.4.1.3. De novo somatic DNA alterations in endometriosis 
In addition to inherited CNVs that are present in all cells of the human body, the 
non-inherited alterations in somatic cells (somatic copy number alterations, 
SCNAs) that arise spontaneously, have gained attention in endometriosis 
5 
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research. The main hypothesis encouraging SCNA studies has been based on 
the idea that endometriosis is a tumor-like disease caused by de novo somatic 
DNA aberrations (Figure 5) that are frequent in malignant neoplasms 
(Beroukhim et al., 2010). How and where these alterations occur is still unclear 
but the primary source of SCNAs in endometriosis could be either the eutopic 
endometrium from which menstrual blood containing endometrial cells with 
changed properties refluxes through the fallopian tubes to peritoneal cavity and 
form lesions or somatic alterations may arise in normal endometrial cells at 
ectopic locations in response to abnormal peritoneal environment.  
 
 
Figure 5. The schematic representation of putative mechanisms of endometriotic lesion 
development through SCNAs. Genomic alterations may occur already in the eutopic 
endometrium (denoted in the right side of the upper panel) or arise in response to 
peritoneal environmental conditions from normal endometrial cells that are refluxed 
during the menstruation into the abdominal cavity (denoted in the left side of the upper 
panel). Lower panel: normal DNA has two copies of each specific genomic region, 
homozygous duplication indicates the presence of 4 copies, hemizygous duplication 3 
copies, hemizygous deletion 1 copy and homozygous deletion indicates a loss of 
specific genomic region. 
 
Different methods have been used (e.g. traditional methods like karyotype 
analysis, fluorescence in situ hybridisation, microsatellite analysis, and genome-
wide methods like CGH, aCGH and exome sequencing) to identify SCNAs in 
eutopic or ectopic endometrial tissues of endometriosis patients (Gogusev et al., 
1999; Guo et al., 2004; Wu et al., 2006b; Zafrakas et al., 2008; Silveira et al., 
2012; Yang et al., 2013) (Table 2). However, the results of these studies have 
19 
not provided a clear consensus about the presence of somatic alterations either 
in endometriotic lesions or eutopic endometria. Some of the studies have 
reported the presence of chromosomal alterations in lesions, more frequently 
gains in chromosomes 1p, 3p, 6q, 17q, and Xq and losses in chromosomes 1p, 
5p, 6q (Gogusev et al., 1999; Wu et al., 2006b; Veiga-Castelli et al., 2010; 
Silveira et al., 2012; Yang et al., 2013), while the study by Zafrakas et al. 
(2008) found no chromosomal aberrations in ectopic or eutopic endometrium 
(Zafrakas et al., 2008). Guo et al. (2004) found several genomic alterations also 
in eutopic endometria of endometriosis patients and hypothesised that these 
alterations could be the proximate cause of endometriosis (Guo et al., 2004). 
Recently, the first study implementing whole-exome sequencing to search 
somatic alterations in endometriosis was conducted by Li et al. (2014) who 
sequenced the exomes of blood DNA and laser capture microdissection (LCM)- 
harvested endometrial cells from eutopic and ectopic endometria of 16 
endometriosis patients and eutopic endometria of 5 healthy women (Li et al., 
2014). A very interesting finding of this study was that DNA originating from 
healthy endometria contains thousands of somatic mutations that are absent in 
blood DNA, indicating the presence of somatic mutations also in endometria of 
healthy women. The overall somatic mutation spectrum in endometria of 
women with and without endometriosis was very similar; however, endo-
metriotic cells from patients had a unique fingerprint and a number of mutated 
genes were related to pathways involved in adhesion processes, chromatin 
modification, cell cycle, DNA repair and regulation of apoptosis (Li et al., 
2014). The authors concluded that most of the mutations are already present in 
the cells of eutopic endometrium in endometriosis patients and nearly all of 
these mutations are probably benign and irrelevant for pathogenesis (Li et al., 
2014).  
Based on the inconclusive results of aforementioned studies it is difficult to 
draw any definite conclusion about the presence and potential role of SCNAs in 
endometriosis pathogenesis and therefore further studies are needed.  
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2.4.2. Transcriptome studies in endometriosis 
Since 2002, around 20 mRNA transcriptome studies applying microarray 
technology have been carried out to reveal the gene expression profile specific 
to eutopic endometria and endometriotic lesions of endometriosis patients. 
Studies focusing only on eutopic endometria of patients and controls (Kao et al., 
2003; Absenger et al., 2004; Matsuzaki et al., 2005; Burney et al., 2007; Sherwin 
et al., 2008; Aghajanova et al., 2011; Fassbender et al., 2012; Tamaresis et al., 
2014) have not provided clear evidence about the importance of transcriptomic 
changes in eutopic endometria to disease pathogenesis. Although variable 
amounts of differentially expressed genes have been reported, with little con-
cordance between the studies (Figure 6A), it has been proposed that the influence 
of menstrual cycle phases has a more pronounced effect on endometrial tran-
scriptome than the presence of endometriosis (Burney et al., 2007; Aghajanova et 
al., 2011; Fassbender et al., 2012).  
 
 
Figure 6. Venn diagrams describing the overlap between the results from different 
transcriptome studies. A. transcriptome studies in eutopic endometria and B. tran-
scriptome studies where endometriotic lesions were compared to eutopic endometria. 
The input for Venn diagrams is based on the literature review and only studies 
presenting differentially expressed gene lists were included. In some studies only the 
top lists (Burney et al., 2007; Hever et al., 2007; Kobayashi et al., 2012) or partial lists 
(Absenger et al., 2004; Eyster et al., 2007; Tamaresis et al., 2014) of genes were 
eligible for analysis. The numbers of studied tissue samples are shown on the figure 
together with the respective references. E, endometriosis endometrium; NE, healthy or 
non-endometriosis endometrium; L, endometriotic lesion; SC, primary endometrial 
stromal cell cultures. 
 
Transcriptome studies in lesions have found a remarkable number of genes with 
altered expression in ectopic endometrial tissue while compared to eutopic 
endometria (Lebovic et al., 2002; Arimoto et al., 2003; Konno et al., 2003; 
Matsuzaki et al., 2004; Hu et al., 2006; Wu et al., 2006a; Eyster et al., 2007; 
Khan et al., 2012; Crispi et al., 2013; Sun et al., 2014). Similarly to the endo-
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metrial tissue studies, the comparison of available gene lists (Eyster et al., 2007; 
Hever et al., 2007; Khan et al., 2012; Kobayashi et al., 2012; Crispi et al., 2013) 
showed that the overlap between these studies was relatively small (Figure 6B) 
and only a small subset of genes (e.g. AEBP1, CXCL2, C3 and C4A) was found 
in more than three studies, while no differentially expressed genes common to 
all studies were reported.  
Beside mRNAs, the first studies focusing on long noncoding RNAs 
(lncRNAs) have been conducted (Sun et al., 2014; Wang et al., 2015). lncRNAs 
are thought to function as regulators of gene expression at almost every stage, 
from targeting epigenetic modification to modulation of mRNA stability and 
translation (Mercer et al., 2013). Authors proposed that many found dysregulated 
lncRNAs may participate in biological pathways related to chromosome 
condensation, nucleosome assembly, and protein–DNA complex assembly, which 
correspond well to the central role lncRNAs play in the epigenetic regulation of 
the genome (Sun et al., 2014). However, the true relevance of lncRNAs in patho-
genesis of endometriosis needs to be elucidated in future studies.  
It should be pointed out that to date no meta-analyses have been conducted 
concentrating on all endometriosis transcriptome data, probably because of the 
insufficient data presented in papers and also because of the poor availability of 
full datasets. Furthermore, the study design differences make the comparison of 
findings even more complicated. For example, lesions from different locations 
(peritoneal lesions/endometriomas) have been compared to healthy or matched 
endometrium, selection criteria for patients and controls have been different, 
used array types vary, and menstrual cycle phases of studied individuals are not 
reported or samples from different menstrual cycle phases have been used. Still, 
despite the low concordance between results, all transcriptome studies have 
found remarkable differences between lesions and eutopic endometria and 
therefore, future large scale studies with carefully planned study design are 
needed to reveal changes truly related to the disease pathogenesis. 
 
 
2.4.3. miRNA studies in endometriosis 
miRNAs are small (typically 22 nucleotides in size) non-coding regulatory 
RNA molecules, which have an important function in modulating the stability 
of specific mRNA targets. Changes in miRNA expression that affect target 
mRNA degradation and/or translation may cause alterations in the dynamic 
balance between miRNAs and their target mRNAs and thereby lead to changes 
in normal physiological status of the tissues. miRNAs have been extensively 
studied in association with different pathologic conditions, among them uterine 
and endometrial disorders such as uterine leiomyoma (Creighton et al., 2010), 
endometrial carcinoma (Banno et al., 2013) and endometriosis (reviewed in 
Gilabert-Estelles et al., 2012). miRNA studies in endometriosis can be divided 
into two groups: studies focusing on endometria of patients and controls, and 
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studies comparing miRNA expression profiles between endometriotic lesions 
and endometrium. 
Some microarray-based miRNA studies describing differences between 
eutopic endometria of patients with endometriosis and healthy women have 
been performed (Burney et al., 2009; Laudanski et al., 2013; Braza-Boils et al., 
2014; Shi et al., 2014; Laudanski et al., 2015). Burney et al. found differential 
expression of two miRNA families, miR-9 (miR-9, miR-9*) and miR-34 (miR-
34b*, miR-34c-5p, miR-34c-3p) in patients with endometriosis (Burney et al., 
2009). A subsequent study by Laudanski et al. reported two miRNAs (miR-483-
5p and miR-629) that were down-regulated in eutopic endometrium of patients 
compared to controls (Laudanski et al., 2013). Authors suggested that lower 
expression of these miRNAs is a consequence of an early defect in the physiolo-
gical activity of the proliferative endometrium, eventually resulting in the 
overgrowth of this tissue outside the uterus (Laudanski et al., 2013). Laudanski 
et al. expanded their previous work and reported the presence of 136 upregulated 
miRNAs in the eutopic endometrium of patients with advanced ovarian endo-
metriosis compared with the eutopic endometrium (Laudanski et al., 2015). 
After validation of 11 miRNAs, only three: miR-5187-3p, miR-3152-5p, and 
miR-30d-5p, revealed borderline significance. Furthermore, authors were not 
able to detect the differential expression of miRNAs they had reported in their 
previous study (miR-483-5p and miR-629) (Laudanski et al., 2013). In the 
study by Braza-Boils et al. (2014) both eutopic endometria from patients and 
controls and endometriotic tissues were studied (Braza-Boils et al., 2014). The 
hierarchical clustering analysis showed clearly that the miRNA expression 
signatures of eutopic endometria of patients and controls were very similar and 
only five miRNAs were found to be differentially expressed (fold change, 
FC > 1.5) in eutopic endometria. Thirty six downregulated miRNAs in endo-
metria of patients were also reported by Shi et al. (Shi et al., 2014). However, 
the comparison of all the results from aforementioned miRNA studies (Figure 
7A) showed only a minute overlap, and only one miRNA (miR-9*) was 
reported to have altered expression in eutopic endometria of endometriosis 
patients in two studies. Is the small overlap a sign that miRNA expression levels 
are not affected in eutopic endometria of endometriosis patients or is it a 
reflection of differences in study design (array platforms/the effect of menstrual 
cycle/ selection of controls etc.), is not clear. 
Genome-wide miRNA studies describing the full spectrum of miRNAs 
expressed in a specific genome (miRNome) of peritoneal lesions or endo-
metriomas have found a number of miRNAs that could be associated with disease 
pathogenesis (Ohlsson Teague et al., 2009; Filigheddu et al., 2010; Hawkins et 
al., 2011; Braza-Boils et al., 2014; Shi et al., 2014). Similarly to endometrial 
studies, the concordance between endometriotic lesion studies is relatively 
small and no differentially expressed miRNAs can be found in all studies 
(Figure 7B). However, subsets of overlapping miRNAs such as miR-200b and 
miR-196b (found in four studies), miR-200a, miR-183, miR-375, miR-200c and  
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Figure 7. Venn diagrams describing the overlap between the results from different 
miRNA studies. A. miRNA studies in eutopic endometria and B. miRNA studies where 
endometriotic lesions were compared to eutopic endometria. miRNAs included into the 
analysis were with FC > 1.5 and p-value < 0.05. The input for Venn diagram is based on 
the literature review and only studies presenting differentially expressed miRNA lists 
were included. Only the top lists of miRNAs were provided in some studies (Burney et 
al., 2009; Laudanski et al., 2013). The numbers of studied tissue samples are shown on 
the figure together with the respective references. E, endometriosis endometrium; NE, 
healthy or non-endometriosis endometrium; L, endometriotic lesion. 
 
miR-29c (found in three studies) and miR-381, miR-133b, miR-429, miR-10a, 
miR-34c-5p, miR-141, miR-449b, miR-509-3-5p, miR-1, miR-182, miR-376a, 
miR-203, miR-93, miR-25, miR-100, miR-20a miR-150 miR-145 miR-99a and 
miR-365 (found at least in two studies) have been repeatedly reported. 
Interestingly, the members of miR-200 family (miR-200a, miR-200b and miR-
141) have been frequently reported to be differentially expressed between 
lesions and endometria. miR-200 family has been shown to target a complex 
network of important transcription regulators like ZEB1 and ZEB2 (E-box-
binding transcription factors 1 and 2) which are transcriptional repressors for  
E-cadherin (Figure 8) (Park et al., 2008). The members of this complex regulate 
two essentially important biological processes – cell migration and epithelial-
mesenchymal transition (EMT), which are supposed to be crucial events for the 
development of endometriosis (Matsuzaki et al., 2012). During the EMT 
process epithelial cells lose their specific features and acquire mesenchymal 
characteristics. It has been shown that these miRNAs are involved in 
maintaining the epithelial nature of the cells by downregulating the E-cadherin 
repressors ZEB1 and ZEB2 and this process is regulated by the double-negative 
regulatory ZEB/miR-200 feedback loop where ZEB1 and ZEB2 bind also to the 
E-box elements located at the promoter regions of the miR-200 family members 
(Bracken et al., 2008; Brabletz et al., 2010). There is strong evidence that 
overexpression of ZEB1/ZEB2 and the subsequent loss of E-cadherin 
expression lead to increased cell invasion and migration, loss of epithelial 
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integrity and thereby could initiate pathological processes (Korpal et al., 2008; 
Park et al., 2008; Romero-Perez et al., 2013). 
 
 
Figure 8. The schematic representation of the miR-200 family members’ role in 
regulation of EMT and mesenchymal-epithelial transition (MET) processes. miR-200 
family members regulate EMT directly by targeting the E-cadherin repressors ZEB1 
and ZEB2 mRNA. ZEB1 and ZEB2 bind also to the promoter regions of the miR-200 
family members, forming double-negative feedback loop.  
 
 
2.4.4 DNA methylation studies in endometriosis 
DNA methylation is one of the most studied epigenetic modifications of DNA, 
involved in regulation of many fundamentally important processes such as 
embryo development, gene expression, genome imprinting, X-chromosome 
inactivation, aging and disease development (reviewed Bird, 2002; Nasu et al., 
2011). DNA methylation, where the cytosine nucleotide is converted by DNA 
methyltransferases into 5´-methylcytosine, occurs mainly in CpG dinucleotide 
rich areas (referred to as CpG islands). While the non-methylated CpG islands 
within the promoter region of the gene are required for the initiation of gene 
transcription, methylation of these CpG islands may result in down-regulation 
or silencing of the gene expression. The genome-wide studies have revealed 
that different cell types and tissues have their specific DNA methylation 
signature (Zhang et al., 2013) and alterations in this well-balanced system are 
suggested to be one possible molecular feature that contributes to the develop-
ment of many human diseases, including endometriosis.  
Recently, extensive progress has been made in identifying global changes in 
the DNA methylation profiles of eutopic endometria (Naqvi et al., 2014), 
eutopic/ectopic endometria (Borghese et al., 2010) and primary cell cultures of 
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eutopic and/or ectopic endometria (Dyson et al., 2014; Yamagata et al., 2014) 
from patients and controls (Table 3). Naqvi et al. investigated eutopic endo-
metria of patients and controls and found 120 differentially methylated (1.5-fold 
or greater difference) genes (Naqvi et al., 2014). In the validation study, where 
authors included markers that have not been previously associated with endo-
metriosis, hypermethylation of MGMT, DUSP22, CDCA2, ID2 and hypo-
methylation of BMPR1B, TNFRSF1B, ZNF681, IGSF21, and TP73 was con-
firmed. Although altered methylation levels of several previously known genes 
(MAFB, HOXD10, and HOXD11) were also confirmed, the different methyla-
tion in PR-B, CYP19A1, SF1, COX2, and ER-β genes that have been previously 
associated with endometriosis was not found.  
DNA methylation profiles of endometriotic lesions or stromal cells ori-
ginating from lesions have been described in three studies (Borghese et al., 
2010; Dyson et al., 2014; Yamagata et al., 2014). The first genome wide DNA 
methylation study conducted by Borghese et al. (2010) utilized methylated 
DNA immunoprecipitation (MeDIP) arrays to profile specific promoters, and 
analysed DNA pools from ovarian endometriomas, DIE and SUP together with 
eutopic endometria (Borghese et al., 2010). They found a large number of 
differentially methylated regions in lesions (229 regions for SUP, 161 regions 
for endometriomas and 108 regions for DIE) compared to eutopic endometria. 
They found that overall methylation pattern in all three subtypes and eutopic 
endometria was similar; however, each subtype of the disease had specific 
regions that were consistently hyper- or hypomethylated. Combination of DNA 
methylation data with endometrioma gene expression data revealed no 
systematic correlation between these datasets; however, 35 genes with altered 
DNA methylation and expression were found and most of these were previously 
not associated with endometriosis. 
A later study by Dyson et al. (2014), compared stromal cells obtained from 
ovarian endometriomas to stromal cells from eutopic endometria, and found 
more than four thousand differentially methylated CpGs (Dyson et al., 2014). 
When differentially methylated genes were compared to gene expression data, 
403 genes with aberrant methylation and expression were identified, among 
them genes from the HOXA cluster, ESR1, NR5A1 and GATA family tran-
scription factors (Dyson et al., 2014). Interestingly, some of these genes such as 
PRKAG2, HOXD10, ZNF22 and ANO1, were also reported in a former study by 
Borghese et al. (Borghese et al., 2010). Most recent study by Yamagata et al. 
(Yamagata et al., 2014) compared DNA methylation profiles between stromal 
cell cultures from endometriomas and eutopic endometria of patients and 
controls. They found 515 CpGs (441 genes) hypomethylated and 368 CpGs 
(329 genes) hypermethylated in stromal cells from endometrioma. The analysis 
of these genes revealed significant enrichment for multiple gene ontology (GO) 
terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, such 
as biological processes of signal transduction, molecular functions of receptors 
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and signalling molecules, development and cytokine-cytokine receptor inter-
actions. Although large numbers of differentially methylated genes were found 
between lesions and endometria, only few differences were seen between cells 
of eutopic endometrium of patients and controls. Based on the results, authors 
postulated that stromal cells from endometrioma are already differentiated into 
other cell types and have a specific fingerprint leading to abnormal cellular 
processes and development of the disease.  
As all previous DNA methylation profiling studies varied in terms of study 
design, microarray platforms used, analysed samples and menstrual cycle 
phases of patients (Table 3) the concordance between the results of these studies 
has remained small and further studies, providing new evidence about the 
involvement of epigenetic alterations in disease pathogenesis, are needed. 
 
2.5. Morphological and molecular changes  
in endometrium during the menstrual cycle 
The endometrium is a unique layer of tissue inside the uterus that undergoes 
cyclic molecular, cellular and functional changes. The growth of endometrial 
tissue is under the firm control of endogenous hormones, cytokines and 
chemokines and during the normal menstrual cycle, which usually lasts 24–35 
days, the fluctuation in sex hormone levels leads to cyclic growth and de-
generation of endometrial tissue. The menstrual (uterine) cycle can be divided 
into three phases: menstrual, proliferative and secretory phase (Figure 9). The 
beginning of the menstrual bleeding is the first day of the menstrual cycle where 
the functional layer is shed and re-epithelisation in parallel with tissue 
breakdown is initiated (Ludwig et al., 1991). Proliferative phase is characterised 
by the rapid growth of endometrial glands, stroma and blood vessels and can be 
histologically separated into sub-stages: early, mid- and late proliferative (P) 
phase; however, this division is rarely used in endometrial biopsy dating as 
morphological changes in endometrial histology are very small (Mazur 2005). 
After ovulation (generally occurring on day 14 of a 28-day menstrual cycle), the 
growth of endometrial glands and stroma continues and reaches its maximum 
thickness during the mid-secretory (MS) phase (days 21–22), where the endo-
metrial glands become tortuous and secretory active. During the late secretory 
(LS) phase (days 23–28), stromal cells increase in size and volume, acquire an 
epithelioid appearance and become predecidual cells. After that, endometrial 
regression begins and highly convoluted glands show apoptosis on day 27, 
which is followed by fibrin-thrombin formation in small vessels and haemor-
rhage with extravasation of erythrocytes into the stroma on day 28. At the 
beginning of the menstruation, the predecidual cells collapse and lose their 
abundant cytoplasm (Mazur 2005). 
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Figure 9. Changes in endometrial tissue structure during menstrual cycle. Menstrual 
cycle phases: ES – early secretory phase; MS – mid-secretory phase and LS – late-
secretory phase.  
 
As during the menstrual cycle significant changes occur in tissue morphology, it 
is evident that there should also be changes at the molecular level. Molecular 
profiling studies in endometria have focused mostly on secretory phase endo-
metrium and tried to find transcriptome markers characteristic for window of 
implantation (Carson et al., 2002; Haouzi et al., 2009; Diaz-Gimeno et al., 
2011; Sha et al., 2011; Hu et al., 2014). There are only a few studies both on 
transcriptome (Ponnampalam et al., 2004; Talbi et al., 2006) and epigenome 
level (Houshdaran et al., 2014) describing the molecular changes in healthy 
endometria throughout the menstrual cycle. Ponnampalam et al. and Talbi et al. 
studied the transcriptome of endometrial samples from different phases of 
menstrual cycle and found more than thousand differentially expressed genes 
across the menstrual cycle and reported a strong relationship between histo-
logical dating and molecular profile across the menstrual cycle. Furthermore, 
the results by Ponnampalam et al. emphasized that growth of endometrial tissue 
during the menstrual cycle is a continuum and grouping endometrial samples 
just based on the numerical menstrual cycle day will inevitably separate some 
very closely related samples into adjacent rather than similar groups (Ponnam-
palam et al., 2004). The involvement of epigenetic mechanisms in healthy 
human cycling endometrial tissue has been studied by Houshdaran et al. (2014), 
who demonstrated that the largest changes in DNA methylation occur between 
proliferative and mid-secretory phase where the endometrial tissue reaches its 
maximal thickness and is ready for embryo implantation (Houshdaran et al., 
2014). They reported 66 differentially methylated CpG sites between MS and P, 
27 CpG sites between ES and P and 22 CpG sites between MS and ES phases. 
As the results from molecular profiling studies of healthy endometrium have 
provided clear evidence that endometrial transcriptome and epigenome are 
changing during the menstrual cycle, it is hard to under-estimate the importance 
of considering menstrual cycle phase also in studies investigating pathologic 
5 
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conditions related to endometrial tissue. The significant impact of menstrual 
cycle phase on the transcriptome of endometrial tissue has also been reported in 
endometriosis studies (Burney et al., 2007; Aghajanova et al., 2011; Fassbender 
et al., 2012) and it has been proposed that the influence of menstrual cycle 
phase could have an even larger effect on endometrial transcriptome than the 
presence or absence of endometriosis (Aghajanova et al., 2011). Therefore, 
studies in eutopic- and ectopic endometria in endometriosis should carefully 
consider normal endometrial molecular changes that occur throughout the 
menstrual cycle to find disease-related changes. 
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3. AIMS OF THE STUDY 
The general aim of the study was to find genomic markers that contribute to 
endometriosis development.  
 
Accordingly, the specific aims were:  
 
1. To explore, whether somatic de novo copy number alterations are present in 
endometriotic lesions and contribute to disease development. 
 
2. To describe the miRNome of endometriotic lesions and to find miRNAs 
related to disease pathogenesis. 
 
3. To reveal whether alterations in endometrial DNA methylation signature are 
common in endometriosis and could be the cause of disease development. 
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4. MATERIALS AND METHODS 
The Research Ethics Committee of University of Tartu approved the study 
protocols and the informed consent forms. All participants signed a written 
informed consent.  
 
 
4.1. Study participants  
Patients undergoing laparoscopy for suspected endometriosis at the Women’s 
Clinic of Tartu University Hospital (Tartu, Estonia, Study I, II and III), Elite 
Clinic (Tartu, Estonia, Study I, II and III) and John Radcliffe Hospital (Oxford, 
UK, Study III) were recruited into the study. All enrolled patients were in re-
productive age and had received no hormonal medications at least three months 
before recruitment. The presence of endometriosis was confirmed during the 
laparoscopy by visual inspection and following histological examination of 
endometriotic lesions. The severity of endometriosis was classified according to 
the American Society for Reproductive Medicine revised classification system 
(ASRM, 1997). The general characteristics of all study subjects are presented in 
Table 4.  
 
Table 4. General characteristics of study participants 
 Study I Study II Study III 
Discovery phase 
Patients with 
endometriosis (n) 
11 2 31 
Stage I–II (n) 3 – 19 
Stage III–IV (n) 8 2 12 
Studied tissues  
(type, n) 
endometria, 11 
lesions, 17 
blood, 11 
endometria, 2 
lesions, 5 
healthy tissue, 4 
endometria, 31 
BMI  23.4±3.3 22.5±0.5  22.3±2.9 
Menstrual cycle phases P (n=8),  
MS (n=1), 
ND (n=2) 
P (n=1), LS (n=1) M (n=4),  
P (n=2), 
ES (n=7),  
MS (n=9), 
LS (n=9) 
Age 36.8±5.2 27.5±0.5 32.0±5.0 
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 Study I Study II Study III 
Controls (n) – – 24 
Studies tissues  
(n, tissue type) 
– – endometria, 24 
Menstrual cycle phases – – M (n=1),  
P (n=3), 
ES (n=1),  
MS (n=17) 
LS (n=2) 
BMI  – – 24±4.4 
Age  – – 34.2±4.7 
Validation study 
Patients with 
endometriosis (n) 
187 30 15 
Studied tissues from 
patients (type, n) 
blood, 187 lesions, 22 
non-diseased tissues, 24
endometria, 9 
endometria, 15 
Stage I–II (n) 94 11 13 
Stage III–IV (n) 93 19 2 
Menstrual cycle phase NA P (n=13), ES (n=3), 
MS (n=13), LS (n=5) 
MS (n=7), LS 
(n=7) 
BMI  NA 22.6±2.9 31.0±3.4 
Age  32.6±6.1 32.4±5.0 20.0±3.9 
Controls (n) 171 14 14 
Studied tissues  
(type, n) 
blood, 171 endometria, 8 
stromal and epithelial 
cells from endometria, 5
endometria, 14 
Menstrual cycle phase NA ES (n=3), MS (n=10) MS (n=7),  
LS (n=8) 
BMI  NA 21.7±2.6 32.0±2.7 
Age 36.0±6.0 30.1±3.8 23.1±5.73 
BMI is presented as mean, kg/m2± standard deviation (SD) and age as mean years ± SD; NA, not 
applicable; M – menstrual phase; P – proliferative phase; ES – early secretory phase; MS – mid-
secretory phase and LS – late-secretory phase. 
 
 
 
Table 4. Continuation    
5 
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Healthy women (n=171) representing the Estonian general population, with no 
medical history of endometriosis were enrolled as controls in Study I. Their 
genomic DNA isolated from blood samples was obtained from the Estonian 
Genome Center of the University of Tartu (Tartu, Estonia). Healthy controls for 
Study II (n=13) were recruited from Nova Vita Clinic (Tallinn, Estonia) and 
Elite Clinic. Healthy controls for Study III were recruited from Nova Vita 
Clinic (n=17), and from John Radcliffe Hospital (n=7). The healthy volunteers 
from Estonia were all in reproductive age (mean age 32, range 23–36 years), 
had at least one child from spontaneous pregnancy no more than 10 years ago, 
had not used hormonal medications three months before recruitment, had a 
regular menstrual cycle (28±5 days); normal serum levels of progesterone, 
prolactin, testosterone, had normal vaginal ultrasound, negative screening results 
for sexually transmitted diseases, no presence of endometriosis or polycystic 
ovary syndrome and were non-smokers. Controls from Oxford were endo-
metriosis-free women undergoing laparoscopy for pelvic pain, subfertility or 
tubal sterilisation. They were in reproductive age (mean age 34, range 26–46 
years) and had not used hormonal medication during previous three months.  
 
 
4.2. Collection and processing of tissue samples 
Peripheral EDTA-blood samples from patients were taken before surgery 
(Study I) and endometrial biopsy samples (Study I, II, III) from patients with 
endometriosis and healthy controls were obtained using an endometrial suction 
catheter (Pipelle, Laboratoire CCD, France). Endometriotic lesions and macro-
scopically healthy surrounding tissues adjacent to the lesions were removed 
during the laparoscopy. Tissue samples were either snap-frozen in liquid 
nitrogen and stored at −80 °C until use (Study I) or were immediately placed 
into RNAlater (Ambion, Inc., Austin, Texas, USA) (Study II, III). After 24-
hour incubation in RNAlater at 4 °C, tissues were stored at −80 °C until use. 
DNA from blood and tissue samples was isolated using QIAamp DNA Mini kit 
(Study I) and Qiagen AllPrep DNA/RNA/miRNA Universal Kit (Study III). 
Total RNA together with miRNA-enriched fraction was extracted using 
MinElute Cleanup kit in combination with miRNeasy Mini kit (Study II). 
 
 
4.3. Description of the study design  
A graphical description of study design together with main findings is presented 
in Figure 10. Briefly, CNV profiling (Study I) was carried out at the Core 
Facility of the Estonian Genome Center, University of Tartu, using the Human-
OmniExpress BeadChip (Illumina Inc., San Diego, CA, USA). DNA from 
matched samples of endometria, LCM-treated endometriotic lesions and 
peripheral blood originating from 11 endometriosis patients was examined.  
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The microarray data was analysed using GenomeStudio software, GT module 
v.3.1 (Illumina Inc), PennCNV (Wang et al., 2007) and QuantiSNP (Colella et 
al., 2007) programs. The presence of one CNV was validated in patients 
(n=187) and controls (n=171) by quantitative real-time PCR (qRT-PCR).  
The miRNA profiling (Study II) from endometrial (n=2) and paired samples 
of peritoneal endometriotic lesions (n=5) and matched healthy surrounding tissues 
(n=4) was performed at Biomedicum Functional Genomics Unit (Helsinki, 
Finland) using Genome Analyzer IIx (Illumina). The sequencing data was 
analysed by miRDeep2 and FastQC (http://www.bioinformatics.babraham.ac.uk/ 
projects/fastqc/) programs. The results were validated in an additional set of 
diseased (n=22) and non-diseased (n=24) tissues, in endometria of patients 
(n=9) and healthy women (n=8) and FACS sorted epithelial and stromal cells 
from five healthy endometria by qRT-PCR. 
The DNA methylation profiling (Study III) from eutopic endometria of 31 
patients and 24 controls was performed at USC Epigenome Center (Los Angeles, 
CA) by using the Infinium HumanMethylation450 BeadChips. The DNA 
methylation data was analysed with R statistical computing environment using 
Bioconductor package Minfi (Aryee et al., 2014) and ChAMP (Morris et al., 
2012). The results were validated using additional endometrial samples from 
patients with endometriosis (n=15) and healthy women (n=14) by direct 
bisulfite sequencing. 
The data analysis was performed in cooperation with Priit Palta (University 
of Tartu, Estonia), Jaak Simm (Tallinn University of Technology, Estonia), 
Tauno Metsalu (University of Tartu, Estonia), Triin Laisk-Podar (University of 
Tartu, Estonia) and Vijayachitra Modhukur (University of Tartu, Estonia). 
 
 
4.4. Laser capture microdissection and histologic 
assessment of endometriotic lesions  
For LCM (Study I), histological sections (10 µm) of the snap-frozen endo-
metriotic lesion biopsies embedded in OCT (Leica, Germany) were mounted on 
PEN membrane (P.A.L.M. Mikrolaser Technology, Germany) microscope 
slides and stained with hematoxylin-eosin (HE) to confirm the presence of 
endometriotic cells. LCM of endometriotic epithelial and stromal cells from 
endometriotic lesions was performed using a PALM laser (MicroBeam, P.A.L.M. 
Mikrolaser Technology) (Figure 11). In Study II, histological assessment of 
endometriotic lesions was performed as follows: RNAlater-preserved preserved 
tissue sections were embedded in OCT and cut (10 μm), mounted on standard 
microscope slides, stained with HE and evaluated histologically. The sectioning, 
examination and tissue collection for miRNA extraction was performed as 
follows: after the trimming, five to ten tissue sections were stained, examined 
and in case of a negative finding, the following 10–15 slices were collected into 
a microtube. The sectioning, examination and collection of the tissue was 
carried on until a positive finding (presence of endometrial epithelial and/or 
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stromal cells) or until all the sample was sectioned through (histologically 
negative finding). In case of a positive finding, the sectioning was stopped and 
the remaining biopsy was added to the tube containing previously collected 
tissue sections. 
 
 
Figure 11. Representative photomicrographs of ectopic endometriotic lesions (section 
of Ligamentum sacrouterina, 10 × magnification, 10 µm HE stained section) before 
A. and after B. LCM.  
 
 
4.5. Fluorescence-activated cell sorting (FACS)  
To analyse the miRNA expression in a pure fraction of endometrial epithelial 
and stromal cells (Study II), the FACS sorted cell populations were obtained 
from five healthy women. Endometrial stromal cells were stained with 
fluorescence-conjugated rat anti-human CD13 monoclonal antibody (1:5 
dilution, clone 1R3-63, R-Phycoerythrin, Novus Biologicals, Cambridge, UK) 
and epithelial cells with fluorescence-conjugated mouse anti-human CD9 
monoclonal antibody (1:20 dilution, clone MEM-61, FITC, Novus Biologicals, 
Cambridge, UK). Target cell populations were sorted directly to QIAzol Lysis 
Reagent (Qiagen, Hilden, Germany) and total RNA was isolated immediately.  
 
 
4.6. Validation studies using quantitative  
real-time PCR (qRT-PCR) 
To detect hemi- and homozygous deletions in 3p14.1 region (Study I) the qRT-
PCR reactions using 7500 Fast Real-Time PCR System (Applied Biosystems, 
Foster City, USA) were carried out using 20 ng DNA, 250 nM forward and 
reverse primers, 1 × HOT FIREPol EvaGreen qPCR Mix Plus (Solis BioDyne, 
Tartu, Estonia) and water in a total reaction volume of 20 µl per well. DNA 
copy number fold changes were calculated using the 2–ΔΔCt method (Livak et al., 
2001).  
5 
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In Study II, five miRNAs: hsa-miR-449a (Applied Biosystems, Assay ID 
001030), hsa-miR-34c-5p (ID 000428), hsa-miR-200a-3p (ID 000502), hsa-
miR-200b-3p (ID 002251) and hsa-miR-141-3p (ID 000463) were selected for 
validation analysis (denoted hereafter as miR-449a, miR-34c, miR-200a, miR-
200b, and miR-141). Two small nucleolar RNAs, RNU44 (ID 001094) and 
RNU48 (ID 001006) showing stable expression in human endometrium (Torres 
et al., 2013) were used as endogenous controls. cDNA synthesis was conducted 
from miRNA enriched RNA fraction with TaqMan® MicroRNA Reverse 
Transcription Kit (Applied Biosystems).  
E-cadherin, ZEB1 and ZEB2 expression levels were determined in 12 paired 
endometriotic lesions’ and adjacent healthy tissue samples. DNase treated 
(TURBO DNA-free™ kit, Ambion Inc., Austin, Texas, USA) RNA (up to 1 µg) 
was converted into cDNA using RevertAid First Strand cDNA Synthesis Kit 
(Thermo-Fisher Scientific Inc. MA, USA). qRT-PCR was performed using 1 × 
HOT FIREPol EvaGreen qPCR Mix Plus (Solis BioDyne) or TaqMan® 
Universal PCR Master Mix, No AmpErase® UNG (Applied Biosystems) and 
following the manufacturer’s instructions. 
 
 
4.7. Validation of DNA methylation array data  
by direct bisulfite sequencing 
In Study III, four CpGs, two from CST11 gene (cg06197930, cg12480562), one 
from PI3 gene (cg19931348) and one from SLC43A3 gene (cg13046608) were 
selected for validation analysis. Bisulfite modification of the endometrial DNA 
samples (500 ng each) was carried out with the EZ DNA Methylation-Gold™ 
kit (Zymo Research) according to the manufacturer’s specifications. PCR primers 
for the bisulfite-treated DNA were designed using MethPrimer (Li et al., 2002). 
The sequencing results were analyzed as described in (Parrish et al., 2012) and 
using Mutation Surveyor software (Softgenetics, State College, PA, USA). 
 
 
4.8. Statistical analysis  
The Venn diagrams describing overlap between miRNA and transcriptome 
studies in endometriosis were created using the online tool InteractiVenn 
(Heberle et al., 2015) (http://www.interactivenn.net/). 
The frequency distribution of the 3p14.1 deletion CNV from Study I was 
analysed using χ2 test (PASW 18.0 software, SPSS, INC. USA).  
In Study II, differential miRNA expression between endometriotic lesions, 
healthy tissues surrounding the lesions and eutopic endometria, was analysed 
using the program R (version 2.15.2) package edgeR (Robinson et al., 2010) 
available in Bioconductor version 2.8 was used. The p-values were adjusted for 
multiple testing using the Benjamini and Hochberg method. miRNA levels with 
false discovery rate (FDR)- adjusted p-values < 0.1 were considered statistically 
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significant. The multidimensional scaling (MDS) plots were created using edgeR. 
The Receiver Operating Characteristic (ROC) curve analysis was performed 
using MedCalc software version 12.7.5 (www.medcalc.org). For Clinical Score 
Formula (CSF) that classifies samples into healthy and endometriosis group 
based on the expression levels of miR-449a, miR-200a and miR-200b, linear 
soft margin Support Vector Machines classifier was trained using package 
e1071 in statistics language and environment R (version 3.0.1). The associations 
between the expression levels of ZEB1, ZEB2, E-cadherin and miR-200a, miR-
200b and miR-141 were analysed by Pearson’s correlation. 
DMRs in Study III were identified using “seqlm” package 
https://github.com/raivokolde/seqlm) in the R environment, utilizing MDL 
based approach described earlier (Lokk et al., 2014). The Benjamini–Hochberg 
FDR was calculated for each probe, with a FDR corrected p-value <0.05 used to 
define DMRs. In order to get optimal DMRs, we limited our search in regions 
where distance between at least three consecutive probes was ≤ 500 bp. General 
characteristics and differences between methylation levels for patients and 
controls obtained from Sanger sequencing were calculated using Studentʼs  
t-test, using a p-value cut-off of p <0.05.  
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5. RESULTS  
5.1. De novo somatic DNA copy number alterations in 
eutopic and ectopic endometrial tissue (Study I) 
The CNV profiles obtained from LCM-treated endometriotic lesions and 
eutopic endometria were compared to those of blood from the same women in 
order to reveal de novo occurred SCNAs (study design is presented in Figure 
10A). The analysis revealed no SCNAs while the endometriotic lesions from 
different locations (peritoneal lesions, superficial lesions from corpus uteri, 
ovarian superficial lesions and endometrioma) and endometria were analysed. 
All inherited CNVs that were present in blood and endometrium were also 
detected in endometriotic lesions, confirming the reliability of LCM DNA for 
SCNA detections by SNP array.  
 
 
5.2. Genomic DNA copy number alterations  
in endometriosis (Study I) 
In order to find genomic inherited CNVs (present in all tissues of the same 
individual) that could be more frequently present in endometriosis patients, 
CNVs of all 11 patients were analysed. Altogether 52 (0–11 per person) 
genomic CNVs with an average region size of 85 kb (ranging from 3 kb to 340 
kb) were found in matched blood, endometrial and ectopic lesions samples. 
Most of CNVs (n=48) were described in the DGV and therefore considered as 
common CNVs. Four CNVs were novel: two hemizygous microdeletions (2p21 
and 14q12) and two hemizygous duplications (1q42.3 and 10q23.1). Five CNVs 
(2p22.3, 3p14.1, 4q13.1, 5q15, 10q11.22) were present in more than one 
patient. As the frequency of the deletion in 3p14.1 was considerably higher in 
our patients than reported in the DGV (45% vs. 8%), the presence of this CNV 
was validated in blood DNA of additional 176 endometriosis patients, and 171 
healthy women from the Estonian general population. However, there were no 
significant differences between the frequency of deleted allele in the patient and 
control group (9.4% vs. 6.4%, p ≥ 0.05).  
 
 
5.3. miRNA profile of endometriotic lesions, surrounding 
healthy tissues and endometrial tissues (Study II) 
In the discovery phase, miRNAs of five peritoneal endometriotic lesions, four 
matched adjacent healthy tissues (two lesions originating from the same 
ligament were matched with the same adjacent healthy tissue) and two eutopic 
endometrial samples from two women with severe endometriosis were sequenced 
using Illumina high throughput sequencing technology (study design presented 
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in Figure 10B). The analysis of miRNA sequencing data showed remarkable 
overlap between miRNA expression patterns of all lesions and adjacent healthy 
tissues of the same patient. The MDS plot (Figure 12) demonstrated that all 
studied tissue pairs of the same patient were closer to each other than to the 
respective endometrium originating from the same patient. Based on the MDS 
plot data it was decided to exclude eutopic endometria from future analysis and 
for determination of lesion-specific miRNA profile, to use only endometriotic 
lesions and healthy adjacent tissues. To reveal miRNAs differently regulated in 
lesions, all lesions were compared to all healthy tissues. The comparison 
identified two miRNAs: miR-34c (FDR adjusted p-value 0.005, FC =16.7) and 
miR-449a (FDR adjusted p-value 0.005, FC = 20.1) that were significantly up-
regulated in endometriotic lesions compared to healthy tissues. The counts of 
both miRNAs in lesions and healthy tissues were remarkably lower than in 
eutopic endometria. 
 
 
Figure 12. Clustering analysis of the miRNA counts in eutopic and ectopic tissue 
samples. Dimension 1 represents different tissue types (endometria, healthy tissues, and 
endometriotic lesions) while dimension 2 denotes different patients. Blue and green 
colours indicate different patients. Red circles represent endometriotic lesions, yellow 
circles adjacent healthy tissues and triangles with patient-specific colour denote 
respective endometria. The tissue samples presented in figure are following: patient 
E101 (blue) – endometrium E1011, lesions E1012, E1014, matched healthy tissue 
E1013; patient E47 (green) – endometrium E471, lesions E473, E475, E478, matched 
healthy tissues E474, E476, E479.  
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5.4. Validation of altered expression of miR-34c, miR-449a 
and miR-200 family in endometriotic lesions, endometrium 
and FACS sorted epithelial and stromal cells (Study II) 
In addition to miR-34c and miR-449a, the sequencing data of patient E47 
samples showed trend to higher expression of miR-200a, miR-200b and miR-
141 in lesions compared to healthy tissues. As previous publications (Filigheddu 
et al., 2010; Hawkins et al., 2011; Braza-Boils et al., 2014; Shi et al., 2014) have 
also proposed altered expression of miR-200 family members in endometriosis, 
these three miRNAs were additionally selected for validation analysis. The 
expression differences of miR-449a, miR-34c and members of miR-200 family 
between peritoneal endometriotic lesions and healthy tissues were determined in 
22 diseased and 24 non-diseased tissue samples (Figure 13). Validation analysis 
confirmed the results obtained from miRNA sequencing and all studied miRNAs 
showed significantly higher expression in endometriotic lesions (FC for miR-
449a = 95.7, miR-34c = 5.9, miR-200a = 6.0, miR-200b = 5.7 and miR-141 = 
11.2) compared to healthy tissue samples (all p < 0.0001). The results of qRT-
PCR indicated that adjacent healthy tissues and histologically unconfirmed 
lesion-like tissue samples had very similar expression levels of the tested 
miRNAs (all p > 0.05) and therefore it was decided to combine both types of 
samples as “non-diseased” group. When expression data was evaluated in the 
combined group, even more significant differences were seen between lesions 
and the non-diseased tissue group (FC for miR-449a = 129.9, miR-34c = 10.2,  
 
 
Figure 13. The expression of selected miRNAs in endometriotic lesions (n=22), 
histologically unconfirmed lesions (n=10) and healthy tissues (n=14) using qRT-PCR. 
The error bars denote SEM (standard error of the mean). * Denotes comparison of 
endometriotic lesions with healthy tissues, p < 0.0001. 
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miR-200a = 10.5, miR-200b = 10.2 and miR-141 = 16.8; p < 0.0001). To test 
whether the expression of these miRNAs is differently regulated in the endo-
metrium of endometriosis patients, the endometria of nine patients with endo-
metriosis and eight healthy women were analysed. However, the results 
revealed no significant expression level differences between the endometria of 
endometriosis patients and controls (all p > 0.05).  
Furthermore, to confirm epithelial cell-specific expression pattern of these 
miRNAs, FACS-separated endometrial epithelial and stromal cells originating 
from five endometria of healthy women were used (Figure 14). Data analysis 
revealed significantly higher expression of studied miRNAs in epithelial cells 
compared to stromal cells (FC for miR-449a = 86.1, miR-34c = 16.7, miR-200a 
= 52.4, miR-200b = 44.6 and miR-141 = 68.4; p < 0.0001) indicating an epithelial 
cell-specific miRNA expression pattern. 
 
 
Figure 14. The expression of miRNAs in FACS sorted epithelial and stromal cells 
using qRT-PCR. The error bars denote SEM.  
 
 
5.5. E-cadherin, ZEB1 and ZEB2 expression  
levels in endometriotic lesions and adjacent  
healthy tissues (Study II) 
As the known target genes of the miR-200 family are E-cadherin, ZEB1 and 
ZEB2, mRNA expression levels of these genes were studied between endo-
metriotic lesions and adjacent healthy tissues in 12 paired tissue samples. E-cad-
herin showed statistically higher expression in endometriotic lesions (t-test, 
p = 0.01) but there were no significant differences in ZEB1 and ZEB2  
44
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expression levels between the diseased and non-diseased samples (t-test, 
p > 0.05). The correlation analysis (Figure 15) showed a significant negative 
correlation between ZEB2 and miR-200a (r = −0.43, p = 0.03), miR-200b  
(r = −0.49, p = 0.01), and miR-141 (r = −0.45, p = 0.02) expression, and a po-
sitive correlation between E-cadherin and miR-200a (r = 0.77, p < 0.001), miR-
200b (r = 0.69, p < 0.001), and miR-141 (r = 0.57, p = 0.02) expression. ZEB1 
mRNA levels did not correlate with miR-200 family expression levels. 
 
5.6. Diagnostic potential of miR-34c, miR-449a, miR-200a, 
miR-200b and miR-141 (Study II) 
As the level of these miRNAs was significantly higher in endometriotic lesions 
than in healthy tissues, the ability of these miRNAs to discriminate endo-
metriotic lesions (n=22) from non-diseased tissues (n=24) was evaluated. The 
ROC analysis revealed that all miRNAs enabled a correct classification of 
diseased and non-diseased tissues (area under the curve – AUC values for miR-
449a, miR-34c, miR-200a, miR-200b and miR-141 were 0.92, 0.81, 0.91, 0.90, 
and 0.83, respectively). The combined signature of five miRNAs showed high 
sensitivity (91.7%) and specificity (95.5%), (AUC = 0.94, CI 0.83–0.99) but the 
subset of three miRNAs – miR-449a/miR-200a/miR-200b – showed the best 
discriminating power with the highest sensitivity (95.8%) and specificity 
(95.5%) (AUC = 0.95, CI 0.83–0.99).  
Based on the expression levels of miR-449a, miR-200a and miR-200b, the 
Clinical Score Formula (CSF) score (CSF score = X × ΔCt of miR-449a + Y × 
ΔCt of miR-200a – Z × ΔCt of miR- 200b – W) was calculated. In CSF score X, 
Y, Z and W denote the coefficients determined by the classifier algorithm which 
are based on the already analysed tissue samples, while ΔCt is a threshold value 
difference of target and reference miRNAs of the study samples. More specifi-
cally, X, Y and Z (parameters for each miRNA) and W (intercept) are found by 
training a Support Vector Machine classifier which finds a linear combination 
of the miRNAs that best separates endometriotic lesions from healthy tissues. 
Based on the CSF score, values lower than 0 indicate that the studied tissue 
samples are endometriotic lesions, and a score above 0 indicates that the studied 
tissue samples are disease-free. The CSF score enabled to distinguish endo-
metriotic tissue samples from lesion-like samples with very high classification 
accuracy (> 95%).  
 
 
5.7. DNA methylation in endometria  
of endometriosis patients and controls (Study III) 
Endometrial samples from 31 endometriosis patients and 24 disease-free 
women, from M (n=5), P (n=5), ES (n=8), MS (n=26) and LS (n=11) menstrual 
cycle phases were used for genome-wide DNA methylation analysis. Study 
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design is presented in Figure 10C. The principal component analysis (PCA) 
clustering of the normalized data showed no significant segregation between 
patients and controls indicating that the overall DNA methylation profile 
between patients and controls was very similar (Figure 16). 
Nevertheless, if we compared the methylation profiles of all patients with 
endometriosis to healthy women, we found 28 DMRs (FDR <0.05, Δβ ranging 
from ˗0.01 to ˗0.16 and from 0.01 to 0.08) from which 16 were associated with 
known genes (PI3, SLC43A3, MGAT5B, MUC4, HIVEP3, FGG, CLCF1, 
CANT1, LTK, AHRR, AKR1B1, APEH, CST11, ELOVL4, HBE1 and NEGR1, 
Table 5). Twelve DMRs were not related to any genes and one of the top-
ranking intergenic DMRs was located on chromosome locus 7p15.2, about 13 
kb upstream from HOXA gene cluster. After adjusting DNA differential 
methylation analysis for different variables like age, nationality, menstrual cycle 
phase and BMI, no DMR remained statistically significant. Menstrual cycle 
phase had the most significant impact on DNA methylation profile according to 
multivariable analysis.  
 
 
Figure 16. Principal component analysis describing DNA methylation data across all 
studied endometrial samples from Estonia and Oxford. The large dots and triangles 
mark overlapping samples. 
 
To confirm the results of microarray analysis, four CpG sites located in the 
promoter regions (two CpGs from CST11 gene, one from PI3 gene and one 
from SLC43A3 gene) were selected for validation analysis by conventional 
bisulphite Sanger sequencing in an extended group of patients and controls from 
LS (n=15) and MS phase (n=14). The correlation analysis between microarray 
and bisulphite sequencing data showed strong correlation (Pearson correlation 
coefficient, PCC > 0.85, p < 0.001) for SLC43A3 and CST11 and moderate 
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correlation (PCC = 0.58, p = 0.07) for PI3. From four analysed CpG sites, only 
the CpG from SLC43A3 gene showed statistically significant differential 
methylation between MS patients and controls (p = 0.03). 
 
Tabel 5. Gene- associated DMRs between women with and without endometriosis 
Chromo-
some 
Start End CpGs in 
region 
Gene name FDR Average 
Δβ  
1 41981789 41982027 4 HIVEP3 0.008 –0.01 
17 74928552 74928737 3 MGAT5B 0.020 0.03 
11 57195025 57195382 4 SLC43A3 0.020 0.03 
20 43802992 43803485 3 PI3 0.020 0.04 
3 195488493 195488922 3 MUC4 0.020 –0.12 
3 195489306 195489782 3 MUC4 0.040 –0.05 
5 434877 435267 4 AHRR 0.020 0.20 
17 76991208 76991378 3 CANT1 0.030 –0.01 
3 49710768 49711095 4 APEH 0.030 0.06 
1 72748607 72749064 4 NEGR1 0.030 –0.004 
20 23434086 23434279 3 CST11 0.030 0.03 
7 134144106 134144288 3 AKR1B1 0.030 0.02 
4 155533784 155534149 3 FGG 0.030 0.04 
15 41803428 41803850 4 LTK 0.030 0.03 
11 5291214 5291692 3 HBE1 0.040 0.06 
11 67141747 67141961 3 CLCF1 0.040 –0.003 
6 80657412 80657436 5 ELOVL4 0.040 0.02 
 
 
5.8. Menstrual cycle-specific DNA methylation signature  
of endometrium (Study III)  
Interestingly, unsupervised hierarchical clustering analysis of methylation data 
revealed two main branches that divided endometrial samples based on the 
menstrual cycle phase rather than diseased/non-diseased status (Figure 17). The 
first branch included all LS phase samples (n=11), four out of five M phase 
(n=4) and some MS phase (n=7) samples, while the other branch included all 
other samples (19 from MS, 8 from ES, 5 from P and one remaining sample 
from M phase).  
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Figure 17. Hierarchical clustering analysis of all endometrial samples included into the 
study. Sample codes starting with E indicate patients with endometriosis and H indi-
cates healthy individuals. Samples with the same index number are duplicates. The 
asterisk indicates samples from the Oxford cohort.  
 
As there was no segregation between patients and controls, both groups were 
combined (altogether 55 individuals) to find menstrual cycle phase-specific 
methylation changes. The studied individuals were divided into five groups (M, P, 
ES, MS and LS phase) according to the menstrual cycle day at the time of 
biopsy collection and to assess the overall methylation pattern characteristic to 
each cycle phase the methylation data of each phase was compared to other 
phases. A large number of differentially hypo- and hypermethylated regions 
(FDR < 0.05) were noticed when either or both M and LS phases were involved 
in comparisons, while only some DMRs were found in comparisons between P, 
ES and MS phases (Table 6). 
While menstrual cycle phase comparisons revealed several differences in the 
methylation pattern, we compared the lists of endometriosis-specific dif-
ferentially methylated genes and regions to the menstrual cycle-specific 
alterations. Results showed that eight out of 16 differentially methylated genes 
found in patients with endometriosis overlapped with the menstrual cycle-
related genes: seven genes (PI3, SLC43A3, MGAT5B, MUC4, HIVEP3, FGG 
and CANT1) from comparison between MS and LS phase and one gene (LTK) 
from M to P comparison. The remaining eight differentially methylated genes – 
AHRR, AKR1B1, APEH, CST11, ELOVL4, CLCF1, HBE1 and NEGR1 were not 
related to the menstrual cycle changes. From DMRs that were not related to any 
genes, five were also found in the lists of menstrual cycle-specific loci. 
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Table 6. The number of differentially hyper-/hypomethylated DMRs and genes between 
menstrual cycle phases 
  
The number of DMRs and genesa (hyper-/hypomethylated) 
M (n=5) P (n=5) ES (n=8) MS (n=26) LS (n=11) 
M (n=5)  
1009/1775 130/189 363/855 288/368 
632/1066 92/116 254/512 208/222 
P (n=5) 
1009/1775 
 
0/0 1/2 3045/1650 
632/1066 0/0 1/0 1768/936 
ES (n=8) 
130/189 0/0 
 
0/5 2806/1208 
92/116 0/0 0/3 1015/635 
MS (n=26) 
363/855 1/2 0/5 
 
2806/1208 
254/512 1/0 0/3 1616/704 
LS (n=11) 
288/368 3045/1650 1727/1050 2806/1208 
208/222 1768/936 1015/635 1616/704 
a The number of DMRs is given in the upper, and the number of differentially methylated genes in 
the lower row of the respective comparison of the menstrual cycle phases. 
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6. DISCUSSION  
In our studies we have used genome-wide approaches to take a deeper look into 
the molecular architecture of endometriotic lesions and endometria of endo-
metriosis patients. We discovered not only new molecular aspects about the 
disease but also brought out several important concerns related to proper study 
design in endometriosis research. In the following sections the relevance of the 
findings in the context of study design, disease pathogenesis and molecular 
diagnostics will be discussed.  
 
 
6.1. Relevance of the findings in the context  
of study design in endometriosis research 
It has been seventeen years since the first endometriosis large-scale molecular 
profiling study was conducted in 1999 (Gogusev et al., 1999). Since then, the 
fast development of new technologies has generated opportunities to get novel 
insights into the complexity of endometriosis at the molecular level. About fifty 
endometriosis studies have used modern, high-throughput technologies to 
uncover the potential mechanisms of disease development but regardless of the 
numerous studies, only slight progress has been made towards uncovering the 
mystery of endometriosis. 
One of the possible reasons why these attempts have not yet answered the 
question why endometriosis develops may be in the low concordance between 
the results of similar studies. Discoveries made in one study are rarely re-
produced by others, most probably because of the variable approaches towards 
study design. Inconsistencies in endometrial and endometriotic lesion biopsy 
collection, processing, and storage methodology, insufficient reports of patient 
phenotype data, small sizes of study groups and differences between 
microarrays, together with variations in data analysis and interpretation, are the 
major affecting factors that could lead to biases and measurement errors 
between studies. Recently, the World Endometriosis Research Foundation 
Endometriosis Phenome and Biobanking Harmonisation Project has made an 
enormous effort to harmonize the standard operating procedures for collection 
of patients’ phenotype data, tissue samples, and processing and storage of bio-
specimens (Becker et al., 2014; Fassbender et al., 2014; Rahmioglu et al., 
2014a), and the proposed guidelines would definitely improve the quality of 
endometriosis molecular profiling research.  
The results of our studies have added three very important concerns related 
to study design in endometriosis research. Firstly, the results of Study I 
accentuated the relevance of considering the individual-specific blood CNV 
profile while examining somatic disease-related changes. Previously, in (a)CGH 
analyses the reference DNA with unknown absolute copy numbers of given 
CNVs has been used to find SCNAs in lesions and endometria. In our study, we 
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compared each patient’s blood to eutopic and ectopic endometria to eliminate 
inter-individual variability in CNVs. Comparisons revealed a number of 
different inherited CNVs (ranging from 0 to 11) in each studied individual and 
this is in good agreement with previous reports suggesting a presence of a 
variable number of CNVs in normal human genome (Sebat et al., 2004; Pinto et 
al., 2007; Teo et al., 2011; Li et al., 2013). It is possible that some of the 
alterations reported in previous endometriosis studies actually represent CNVs 
that are present in all tissues of studied individuals, rather than endometriotic 
lesion-specific SCNAs. Based on our results, we suggest that instead of pooled 
reference DNAs, genomic DNA from blood should always be used to determine 
the background information of individual CNVs while searching SCNAs from 
endometriotic lesions. 
Secondly, in Study II we saw a significant impact of studied tissue-content 
on miRNA signature. In studies investigating endometriotic lesions, little 
attention has been paid to cellular composition of lesions and majority of 
endometriosis studies have used entire biopsied samples where the proportion 
of surrounding tissue is variable and may even be larger than the amount of 
endometrial epithelial and stromal cells. Our data demonstrate that miRNA 
profiles of endometriotic lesions were more similar to those originating from the 
peritoneal tissue than those from respective endometria, meaning that com-
parison of two different tissues (endometrium vs. lesion that is a mixture of 
endometrial and peritoneal cells) with their own specific miRNA profiles brings 
out differences between tissue types rather than differences related to the 
disease. However, although the miRNA profile of peritoneal endometriotic 
lesions was largely masked by the surrounding peritoneal tissue, we were able 
to find a signature of five miRNAs that were more highly expressed in endo-
metriotic lesions compared to macroscopically healthy peritoneal tissue. Further 
analysis confirmed that these five miRNAs (miR-200a, miR-200b, miR-141, 
miR-449a and miR-34c) were more highly expressed in endometrial epithelial 
cells and therefore it was concluded that higher expression levels of these 
miRNAs are not related to different characteristics of endometrial cells in eu- or 
ectopic locations, but rather reflect the presence of endometrial epithelial cells 
in peritoneal tissue. Therefore, based on our results and the fact that tissue-
specific variability in miRNA levels (Vrba et al., 2011), DNA methylation 
(Zhang et al., 2013; Lokk et al., 2014) and in gene expression does exist, the 
normal variability between different tissue types should be taken into account 
while searching molecular markers for endometriosis. Tissue-specific changes 
may partially explain the discordances in results between molecular profiling 
studies where entire lesion tissue biopsies from distinct locations (peritoneal, 
ovarian, intestinal etc.) are compared to eutopic endometria, and this issue 
should be taken into account when interpreting the results of such studies.  
Thirdly, in Study III, a significant influence of menstrual cycle phases on 
endometrial methylome was noticed. There is evidence from transcriptome 
(Ponnampalam et al., 2004; Talbi et al., 2006) and epigenome (Houshdaran et al., 
2014) studies that molecular changes in healthy endometria occur throughout 
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the menstrual cycle. Also, menstrual cycle-specific changes have been found in 
endometriosis transcriptome studies (Burney et al., 2007; Aghajanova et al., 
2011; Fassbender et al., 2012) but their influence on endometrial epigenome has 
not been considered in endometriosis research. As the tissue samples from 
previous epigenome studies in endometriosis were either from proliferative 
(Dyson et al., 2014) or secretory (Borghese et al., 2010) phase or with no infor-
mation about the menstrual cycle (Naqvi et al., 2014; Yamagata et al., 2014), it 
could be that at least some of the reported differences between lesions and 
endometrium may arise from the variability of samples in respect of menstrual 
cycle phases. We found a large number of DMRs between samples from dif-
ferent menstrual cycle phases, accentuating the importance of considering 
normal cyclic epigenetic changes while searching disease-specific molecular 
markers. Based on our data and previous reports, we suggest that menstrual 
cycle phase is an extremely important issue that should be taken into account 
while planning molecular profiling studies and not only in eutopic endometria 
but also in endometriotic lesions. 
Taken together, the results of our studies highlighted the relevance of proper 
study design that could have a significant impact on the overall outcome and 
interpretation of the results. We believe that the new knowledge about the 
normal variability in CNVs, tissue-specific molecular patterns and impact of 
menstrual cycle on the molecular profile of endometrial tissue, will help to 
clarify the global picture of the disease. 
 
 
6.2. Relevance of the findings in the context of 
endometriosis pathogenesis 
All studies presented in this thesis were aimed to search for potential 
mechanisms that are relevant in endometriosis pathogenesis. Study I was driven 
by the idea that de novo occurred SCNAs are associated with disease patho-
genesis. In Study II we searched for the disease-specific miRNA signature from 
lesions and in Study III we investigated epigenetic alterations in endometria to 
shed light on the molecular events triggering the disease development. However, 
the results of Study I contradicted the majority of the preceding studies re-
porting the presence of unique SCNAs in endometriotic lesions (Gogusev et al., 
1999; Wu et al., 2006b; Veiga-Castelli et al., 2010; Silveira et al., 2012; Li et 
al., 2014) as we found no SCNAs associated with endometriosis development. 
The most probable reason explaining our discordant results may again be 
hidden in the methodological differences. Most studies reporting large numbers 
of somatic alterations have used CGH or aCGH methods (Gogusev et al., 1999; 
Wu et al., 2006b; Veiga-Castelli et al., 2010; Silveira et al., 2012; Yang et al., 
2013). Although CGH is a valuable method for discovering SCNAs, it has been 
shown that some G-C-rich chromosomal regions (1p, 16p and chromosomes 19 
and 22) tend to give false-positive results (Karhu et al., 1997; Veiga-Castelli et 
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al., 2010). Also, it could be that some of the genomic alterations reported in 
earlier studies are caused by whole genome amplification (WGA) used for 
multiplying the minute amounts of LCM DNA prior to CGH (Wu et al., 2006b; 
Silveira et al., 2012). WGA-generated amplification artefacts can create false 
deletions and duplications and therefore it is not an ideal method for DNA 
amplification before CGH arrays (Talseth-Palmer et al., 2008). In our study the 
SNP genotyping array was used where the amount of required DNA is con-
siderably smaller than in (a)CGH and therefore there was no need to use WGA. 
Furthermore, we cannot exclude the possibility that differences in findings 
might be caused by the selection of studied tissue samples as there is evidence 
from ovarian cancer studies that at least some of endometriotic lesions may be 
premalignant with diverse malignant potential (Oral et al., 2003). However, 
based on our results we believe that molecular mechanisms other than 
chromosomal rearrangements most likely underlie the initiation and progression 
of endometriosis. 
In Study II we detected five miRNAs- miR-34c, miR-449a, miR-200a, miR-
200b and miR-141 which were significantly up-regulated in endometriotic lesions 
compared to healthy tissues. Interestingly, almost all these miRNAs (except for 
miR-449a) have been repeatedly associated with endometriosis pathogenesis 
(Figure 7B). miR-34c and miR-449a, are classified as one family because of 
their highly similar secondary structures and seed sequence. It has been sug-
gested that members of this family have tumor-inhibitory effects and are capable 
of mediating cell cycle arrest and apoptosis via the p53 signalling pathway 
(reviewed in Lize et al., 2011). While the relevance of miR-449a in endo-
metriosis has not been described earlier, the altered expression levels of miR-
34c in endometriotic lesions and also in eutopic endometrium of endometriosis 
patients have been mentioned (Burney et al., 2009; Ohlsson Teague et al., 2009; 
Hawkins et al., 2011) but the results of our study did not confirm differential 
expression of miR-34c between eutopic endometria of patients and controls. 
Therefore, the potential role of this miRNA in endometriosis pathogenesis is 
currently unclear. 
Further, we found that miR-34c, miR-449a and members of miR-200 family 
were more highly expressed in FACS-sorted endometrial epithelial cells than in 
stromal cell. The higher expression of miR-200 in epithelial cells is in good 
concordance with previous reports showing that members of the miR-200 
family are actively involved in maintaining the epithelial nature of cells (Park et 
al., 2008) and are involved in regulation of EMT and its reverse process, MET 
(reviewed in Hill et al., 2013). Previous studies have shown significant down-
regulation of these miRNAs in endometriotic lesions compared to endometrial 
tissue (Ohlsson Teague et al., 2009; Filigheddu et al., 2010; Hawkins et al., 
2011). The recent functional study using endometriotic cell lines has confirmed 
that up-regulation of miR-200b results with down-regulation of ZEB1 and ZEB2 
and up-regulation of E-cadherin that in turn leads to decreased cell invasiveness 
and motility (Eggers et al., 2016). In our study, the gene expression of miR-200 
targets ZEB1/ZEB2 was not different in lesions compared to healthy tissues but 
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E-cadherin showed significantly higher expression. However, the correlation 
analysis showed negative correlation between miR-200 family members and 
ZEB2 levels and positive correlation with E-cadherin, confirming the effect of 
miR-200 family to ZEB1/ZEB2 expression. Nevertheless, as our results showed 
that miRNA expression levels of surrounding tissue mask those in ectopic endo-
metrial cells, we suggest that pure populations of endometrial and endometriotic 
cells should be explored to determine, whether and how these miRNAs are 
associated with endometriosis pathogenesis.  
Genome-wide DNA methylation studies have suggested that the abnormal 
DNA methylation pattern in endometria and lesions of endometriosis patients 
could be one potential cause leading to the development of endometriosis 
(Borghese et al., 2010; Dyson et al., 2014; Naqvi et al., 2014; Yamagata et al., 
2014). The results from Study III demonstrated that the epigenetic signature of 
endometrial tissue in patients and controls was highly similar and endometrial 
samples clustered according to the menstrual cycle phase rather than diseased/ 
non-diseased status. However, we found 28 DMRs between patients with 
endometriosis and controls when menstrual cycle phases were not taken into 
account. Sixteen of them were located in known genes and from those eight 
genes (PI3, SLC43A3, MGAT5B, MUC4, HIVEP3, FGG, CANT1 and LTK) 
were also among the menstrual cycle phase-dependent genes. The remaining 
eight genes (AHRR, AKR1B1, APEH, CLCF1, CST11, ELOVL4, HBE1 and 
NEGR1) could be attractive candidate genes for endometriosis; however, none 
of the previous DNA methylation studies have reported differential methylation 
of these genes in association with endometriosis. Additionally, it should be 
pointed out that the overall magnitude of the methylation differences was rather 
small. How small-scale changes in DNA methylation level are associated with 
the disease pathogenesis, what is their biological significance and whether they 
are the cause or the consequence of the disease, is currently unknown. Further-
more, it is not clear how the small-scale DNA methylation changes could affect 
gene expression. When we compared our results to a gene expression study by 
Tamaresis et al. (Tamaresis et al., 2014), it was evident that several genes 
showing differential methylation in our study (such as AHRR, APEH, ELOV4, 
PI3, SLC43A3, MUC4, CANT and CLCF1) revealed also differential expression 
between patients and controls from certain menstrual cycle phases.  
When looking at differentially methylated genes in endometriosis, we saw 
some genes that might be interesting from a biological point of view, such as 
AKR1B1, AHRR and SLC43A3. AKR1B1 catalyses the formation of prostag-
landin F2α (PGF2α), and is shown to be widely expressed in normal endo-
metrium and myometrium (reviewed in Rizner, 2012). Concurrently increased 
synthesis of prostaglandin PGF2α (that acts as a vasoconstrictor and induces 
myometrial contraction) and prostaglandin E2 (acting as a vasodilator, leading 
to increased edema) in endometrium has important implications in menstruation 
(reviewed in Rizner, 2012). Significant increase in AKR1B1 immunoreactivity 
in a subset of stromal cells in the LS and M phase endometrial tissue has been 
reported (Catalano et al., 2011). Furthermore, in a very recent publication it was 
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shown that AKR1B1 mRNA and protein levels were significantly higher in 
ovarian lesion samples of endometriosis patients compared to eutopic 
endometria of healthy women when secretory phase samples were compared 
but there were no differences between proliferative phase samples (Sinreih et 
al., 2015). A similar menstrual cycle-dependent expression difference was 
demonstrated in comparisons between eu- and ectopic endometria of the same 
individuals (Rakhila et al., 2013) but interestingly, this study found no dif-
ferences between endometria of healthy women and endometriosis patients’ 
eutopic or ectopic endometria. Although we did not see differential methylation 
of AKR1B1 between menstrual cycle phases, cyclic epigenetic changes could 
still be present; however, as most of our specific subgroups were relatively 
small, it is likely that we were not able to detect all potential changes.  
Also, one of the differentially methylated genes in our study was AHRR, 
which shows increased gene expression in fetal tissues exposed to environ-
mental or even lower levels of bisphenol (Nishizawa et al., 2005). It has been 
proposed that developmental exposure to environmental toxins may induce 
irregular methylation patterns and thereby permanently alter the expression of 
AHRR (Aragon et al., 2008). In utero exposure to endocrine disruptor bisphenol 
could be one potential cause triggering the abnormal fetal endometrial cell 
migration into ectopic location, as mice exposed in utero to bisphenol exhibited 
an endometriosis-like phenotype (Signorile et al., 2010b). 
Furthermore, our validation analysis confirmed differential methylation of 
CpG in SLC43A3 promoter; however, only between the MS- phase patients and 
controls indicating influences both from disease and menstrual cycle phase. 
SLC43A3 is a purine-selective nucleobase transporter (Furukawa et al., 2015) 
shown to be expressed during embryogenesis (Stuart et al., 2001) but its possible 
role in endometrium or endometriosis development remains to be elucidated.  
Based on our results we propose that although the epigenetic modifications 
are probably not the primary source contributing to endometriosis development, 
the possible role of small-scale alterations in endometrium found in this study is 
intriguing and worth further studies.  
 
 
6.3. Relevance of the findings in the context  
of molecular diagnostics 
To date, there is no molecular test for endometriosis and histological verification 
of endometrial glands and/or stromal cells of biopsied samples is still needed to 
confirm the diagnosis of endometriosis. Although histological evaluation of 
biopsies is routinely used in everyday practise, a number of previous studies 
have demonstrated that almost half of the surgical specimens removed during 
laparoscopy are not confirmed in the following histological assessments (Moen 
et al., 1992; Stratton et al., 2003; Stegmann et al., 2008; Fernando et al., 2013) 
and some of the removed biopsies are lesion-like structures that include fibrosis, 
inflammatory changes and normal peritoneum (Wanyonyi et al., 2011). Besides 
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traditional HE staining-based histological evaluation, immunohistochemistry 
(IHC) analysis with antibody against cell-surface metallo-endopeptidase CD10 
has been used to improve the recognition of ectopic stromal cells (Sumathi et 
al., 2002). Although the added value of CD10 IHC in case of uncertain diag-
nosis and atypical endometriosis has been confirmed and there is evidence that 
this will significantly increase the diagnostic rate when combined with HE 
staining (Potlog-Nahari et al., 2004) there are also possible limitations using 
CD10 for diagnostics. The major shortage is that the CD10 IHC does not detect 
only endometrial stroma but also lymphocytes and this could give false positive 
results in case of tissue samples with lymphoid infiltration. Therefore, for 
correct diagnosis, the visualisation of epithelial glandular structures using HE 
staining is still needed.  
In Study II, we found that the expression signature of a subset of three 
miRNAs, miR-449a/miR-200a/miR-200b that are mostly expressed in endo-
metrial epithelial cells, enables to separate endometriotic lesions from non-
diseased tissues with a sensitivity of 95.8% and specificity of 95.5%, and there-
fore a molecular test based on these miRNAs offers an alternative to routine 
histological assessment. During the routine histological assessment, several 
tissue sections from different parts of the biopsy are examined and if the 
proportion of endometriotic cells in biopsied specimen is minute, the presence 
of endometrial stromal and epithelial cells may be missed. The advantage of a 
molecular miRNA-based test is that it would allow the evaluation of the entire 
biopsy at once giving accurate diagnosis with high sensitivity and specificity. 
Furthermore, there is no need for a highly experienced pathologist to perform 
and interpret the analysis.  
However, it should be pointed out that although we found a well-performing 
miRNA molecular signature that could be of help in endometriosis diagnostics, 
the usability of this test as an independent diagnostic tool in everyday diag-
nostics is still too ambiguous and more markers confirming also the presence of 
endometrial stromal cells (such as CD10) and excluding other pathologic 
changes, should be added. Still, we believe that miRNA-based molecular diag-
nostic tests are very promising and would offer a good alternative to traditional 
histological assessment.  
 
 
6.4. Study limitations  
Some limitations of the studies presented in the current thesis should be 
acknowledged. As the cost of high-throughput technologies is relatively high, 
the sample sizes used in all our studies have been rather small, thus the studies 
are relatively underpowered to see small and subtle differences between 
investigated tissues. Furthermore, the variance of individual measurements has 
a larger effect in case of small study groups. It is known that different subtypes 
of endometriosis with diverse malignant potential exist (Oral et al., 2003); 
therefore, as Study I revealed no somatic alterations in lesions, we may assume 
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that none of our samples was a pre-malignant lesion. Although the prevalence 
of ovarian cancer arising from atypical ovarian endometriosis (ranging from 
0.7% to 17%) is small (Grandi et al., 2015) and the malignant transformation of 
superficial peritoneal lesions is extremely rare (Marchand et al., 2013), we 
cannot exclude the possibility that some of the previous studies, reporting large 
number of chromosomal alterations, have studied pre-malignant samples. Also, 
in this study we used SNP microarray to determine genomic alterations and 
therefore it could be that some of the existing rare SCNAs might be missed as 
the probe distribution on a SNP array depends on the availability of informative 
SNPs throughout the genome.  
In the miRNA sequencing study (Study II), only peritoneal endometriotic 
lesions were used to determine the discriminative power of the miRNA sig-
nature (miR-449a/miR-200a/miR-200b) and therefore, we cannot assure that the 
proposed molecular test is valid for other types of endometriosis (endo-
metrioma, extra-genital endometriosis etc.). Although our endometrial DNA 
methylation study (Study III) was the largest that has been performed so far, the 
number of studied samples was still too small to obtain sufficient study power 
for detection of small scale DNA methylation changes between patients and 
controls. Furthermore, the size of some menstrual cycle phase groups remained 
relatively low and restricted the possibility to compare patients and controls 
from each phase separately. Also, histological endometrial dating was available 
only for healthy volunteers from MS group. It could be assumed that the self-
reported menstrual cycle day is less accurate for menstrual cycle phase dating 
and it may have some negative impact on menstrual cycle phase-specific 
analysis. 
 
 
6.5. Future perspectives  
The results presented in this thesis suggest that analysis of entire biopsied 
specimens does not provide clear insight into the molecular changes occurring 
inside the lesions. To shed light on true changes without any contamination 
from adjacent tissues/cells, the pure populations of endometrial stromal, 
epithelial and stem cells from lesions are needed. Therefore, in my opinion the 
major challenge in future endometriosis research is not related to the research 
methodology or data analysis per se, as molecular technologies enabling 
analysis of single cells are already available, but are rather associated with diffi-
culties related to obtaining specific single cells or cell populations from lesions. 
Previously, we have used LCM technique (Study I) for isolating endometrial 
epithelial and stromal cells from lesions but as DNA and RNA quality obtained 
by this methodology varies largely (Aaltonen et al., 2011; Cummings et al., 
2011) this method would probably not be the first choice. In our recent study 
(Krjutskov et al., 2016) we used combinations of fluorescently labelled anti-
bodies (CD13 and CD9) that are shown to be markers of endometrial stromal 
and epithelial cells (Kato et al., 2007) and FACS to isolate single cells or cell 
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populations from endometrial biopsies. We believe that this methodology can 
be successfully transferred to endometriotic lesion studies to obtain sufficient 
amounts of pure endometrial stromal and epithelial cells for down-stream 
analysis. Only biological data from pure cell populations from lesions could 
uncover the true molecular changes behind the disease and open the doors for 
new ideas for development of diagnostic methods and disease-specific treatment.  
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7. CONCLUSION 
Based on the results, the following conclusions can be made: 
 
1. No SCNAs were present in eutopic or ectopic endometria in our study group 
and molecular mechanisms other than chromosomal rearrangements most likely 
contribute to the initiation and progression of endometriosis. 
 
2. The miRNA expression in surrounding peritoneal tissue masked most of the 
miRNA expression differences that could originate from a small proportion of 
endometrial cells inside the lesion and therefore only miRNAs with large 
expression differences can be seen. 
 
3. All upregulated miRNAs (mirR-34c, miR-449a, miR-200a, miR-200b and 
miR-141) reflected the presence of endometrial epithelial cells in lesions and 
thus were good markers to discriminate true endometriotic lesions from lesion-
like tissue structures. The expression signature of three miRNAs, miR-
449a/miR-200a/miR-200b offers a good alternative to routine histological 
examination for the accurate assessment of endometriotic lesions. 
 
4. Endometrial DNA methylation signature in women with and without 
endometriosis was highly similar but largely influenced by the menstrual cycle 
phase. Epigenetic modifications in endometrium are probably not the primary 
contributor to endometriosis development. 
 
5. Normal epigenetic changes occurring in endometrium across the menstrual 
cycle phases should be considered when looking for disease-specific DNA 
methylation markers. 
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SUMMARY IN ESTONIAN 
Endomeetriumi ja endometrioosikollete molekulaarse  
profiili iseloomustamine 
Endometrioos on tõsine ja sage günekoloogiline haigus, mida iseloomustab endo-
meetriumi-laadse koe paiknemine ja toimimine väljaspool emakaõõnt. Sarnaselt 
normaalsele endomeetriumi koele, kus menstruaaltsükli jooksult toimub koe 
kasvamine ja irdumine, on ka kõhuõõnes paiknevad endometrioosikolded 
menstruaaltsüklist mõjutatud. Kõhuõõnes tsükliliselt veritsevad kolded kutsu-
vad esile põletikulisi ja liitelisi protsesse, mis põhjustavad alakõhuvalusid ning 
sageli ka viljatust. Arvatakse, et ligikaudu pooltel viljatutest naistest võib vilja-
tus olla tingitud just endometrioosist. Endometrioosi diagnoosimiseks puuduvad 
siiani mitte-invasiivsed meetodid ning korrektne diagnoos põhineb laparos-
koopilisel operatsioonil ja kollete histoloogilisel uuringul. Seetõttu on baas-
teaduslikud uuringud, mis aitaksid leida haigust põhjustavaid molekulaarseid 
muutusi nii endometrioosikolletes kui endomeetriumis, väga olulised.  
Vaatamata ulatuslikele uuringutele ei ole siiani selge, kuidas endomeetriumi 
rakud kõhuõõnde satuvad, miks nad seal kinnituvad ja hakkavad kasvama vales 
kohas. Endometrioosi patogeneesimehhanismide uurimisele on oluliselt kaasa 
aidanud mikrokiibi- ja sekveneerimistehnoloogiate kiire areng, mis võimaldab 
korraga saada suurt hulka bioloogiliselt olulist informatsiooni. Tänaseks on 
teostatud ligikaudu 50 erinevat molekulaarse profiili määramise tööd, kus 
kirjeldatakse endomeetriumis ja endometrioosikolletes toimunud muutusi. Nii 
on välja toodud, et sarnaselt kasvajatele on ka endometrioosikoldeid moodus-
tavates rakkudes toimunud somaatilised DNA koopiaarvu muutused. Samuti on 
endometrioosi kujunemisega seostatud muutusi lühikeste mittekodeerivate 
mikroRNA (miRNA) molekulide ekspressioonis, mis omakorda mõjutab valke 
kodeerivate geenide avaldumist transkriptsioonijärgselt. Hiljutised uuringud on 
välja toonud DNA metülatsioonimustri muutuste võimaliku rolli endometrioosi 
tekkes. Kuigi molekulaarse profiili määramise uuringud on näidanud muutusi 
endometrioosikollete DNAs, miRNA-de tasemetes ja metülatsiooniprofiilis, on 
erinevate uuringute tulemused siiski olnud sageli vastukäivad ning haiguse 
võimalikke patogeneesimehhanisme pole siiani suudetud selgitada. Varasemate 
uuringute tulemuste vähene kattuvus viitab suure tõenäosusega probleemidele 
katsete disainis ja seetõttu on väga oluline juba uuringut planeerides pöörata 
tähelepanu võimalikele kitsaskohtadele, mis võiksid saadud tulemusi mõjutada.  
 
 
Uurimistöö eesmärgid 
Käesoleva uurimistöö eesmärgiks oli tuvastada võimalikud endometrioosi kuju-
nemist põhjustavad genoomsed muutused nii endometrioosikolletes kui ka 
endomeetriumis, kasutades selleks hoolikalt valitud katseskeemi ja mikrokiipi-
del ning süvasekveneerimisel põhinevaid tehnoloogiaid. 
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Sellest tulenevalt olid töö alameesmärgid järgmised:  
1.  Tuvastada de novo somaatiliste kromosomaalsete aberratsioonide olemasolu 
endometrioosikolletes ja endomeetriumis ning määrata nende võimalik 
olulisus endometrioosi patogeneesis.  
2.  Kirjeldada ja leida endometrioosikolletele iseloomulik miRNA-de profiil, 
mis aitaks välja selgitada haiguse võimalikke tekkepõhjuseid.  
3.  Selgitada välja DNA metülatsioonimustri erinevused tervetel ja endomet-
rioosiga naiste endomeetriumites ning leida võimalikud haigusega seotud 
metülatsiooni markerid. 
 
 
Metoodika 
Käesolevas uuringus osalenud endometrioosiga naised värvati Tartu Ülikooli 
Kliinikumi naistekliinikust, Elite Kliinikust või John Radcliffe (Oxford, UK) 
haiglast. Kõik uuringus osalenud naised allkirjastasid uuringus osalemise 
nõusoleku vormi ja täitsid reproduktiivanamneesi käsitleva küsimustiku. Kont-
rollgrupi naiste vere- ja koeproovid pärinesid kas TÜ Geenivaramust, Nova Vita 
Kliinikust, Elite Kliinikust või John Radcliffe haigla patsientidelt. Kõik uurin-
gus osalenud naised olid reproduktiivses eas ja ei olnud tarvitanud hormonaal-
seid preparaate uuringule eelnenud kolme kuu jooksul. 
Somaatiliste DNA koopiaarvude tuvastamiseks kasutati 11 patsiendi endo-
meetriumi, vere ja laserpüüdur mikrodissektsiooni abil eraldatud endometrioosi-
kolde DNAd, mida analüüsiti SNP-mikrokiipidega. Uuringus valideeriti üks 
DNA koopiaarvu muutus 187 patsiendi ja 171 kontroll-indiviidi vere DNAst, 
kasutades kvantitatiivset reaal-aja PCR meetodit (qRT-PCR). miRNA-de pro-
fiili tuvastamiseks süvasekveneeriti kahe naise endomeetriumist, endometrioosi-
kolletest ja kollet ümbritsevast tervest koest pärinev RNA. Endometrioosikolle-
tes kõrgemalt ekspresseerunud miRNA-de tasemed valideeriti endometrioosiga 
ja endometrioosita naiste koeproovides qRT-PCR meetodil. Endomeetriumi 
strooma ja epiteeli rakud eraldati fluorestsents-aktiveeritud läbivoolutsütomeet-
riga. DNA metülatsiooniprofiil määrati 31 endometrioosiga ja 24 endometrioosita 
naisel kasutades mikrokiipe. Uuringu tulemused valideeriti 15 endometrioosiga 
ja 14 endometrioosita naise endomeetriumi bisulfit meetodil töödeldud DNA 
Sanger sekveneerimise abil. 
 
 
Tulemused ja järeldused 
1.  Endometrioosiga naiste endometrioosikolletes ja endomeetriumis ei ole 
toimunud suuremahulisi somaatilisi DNA koopiaarvu muutusi, mis võiksid 
olla seotud endometrioosi kujunemisega.  
2.  Kasutades endometrioosikollete uurimisel laparoskoopia käigus saadud bi-
opsiaid, ei ole ümbritseva terve koe mõjude tõttu võimalik määrata kolletele 
iseloomulikku miRNA-de mustrit. Siiski suutsime tuvastada viis miRNA-t 
(mirR-34c, miR-449a, miR-200a, miR-200b ja miR-141), mille ekspressioon 
on kolde rakkudes tunduvalt kõrgem võrreldes kollet ümbritseva terve 
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koega. Kolde ja endomeetriumi koeproovide võrdlus näitas aga suurt erine-
vust, mis tulenes suuresti kollet ümbritseva koe mõjudest. Sellest saame 
järeldada, et haigusele iseloomulike miRNA tasemete muutuste tuvasta-
miseks tuleb arvesse võtta iga koetüübi normaalset miRNA profiili ja vältida 
endometrioosikolde võrdlemist endomeetriumiga, mis sisaldab suurel määral 
kudet, millel ta paikneb ja vaid vähesel hulgal endomeetriumi spetsiifilisi 
rakke.  
3.  Endometrioosikolletes kõrgemalt ekspresseeritud miRNA-d, (mirR-34c, 
miR-449a, miR-200a, miR-200b ja miR-141) peegeldasid eelkõige endomeet-
riumist pärineva epiteeli rakkude olemasolu kolletes. Kuna histoloogilise 
uuringu käigus ei suudeta alati endometrioosikoldeid kolde-laadsetest 
kudedest eristada, siis pakkusime välja parimat sensitiivsust ja spetsiifilisust 
näidanud kolme miRNA kombinatsioonil (miR-449a/miR-200a/miR-200b) 
põhineva molekulaarse testi endometrioosikolde tuvastamiseks ja endomet-
rioosi diagnoosi kinnitamiseks. Väljapakutud endometrioosikolde moleku-
laarne test on hea alternatiiv praegu kasutuses olevale histoloogilisele 
uuringule.  
4.  Endomeetriumi DNA metülatsioonimuster endometrioosiga ja endomet-
rioosita naistel oli väga sarnane ja seetõttu võib oletada, et endomeetriumi 
epigeneetilised muutused ei oma haiguse kujunemises peamist rolli.  
5.  Endomeetriumis toimuvad normaalsed epigeneetilised muutused kogu 
menstruaaltsükli jooksul ja seetõttu tuleb haiguseseoseliste DNA metülat-
siooni-markerite otsimisel seda kindlasti arvestada.  
 
  
63 
REFERENCES 
Aaltonen KE, Ebbesson A, Wigerup C, Hedenfalk I. Laser capture microdissection 
(LCM) and whole genome amplification (WGA) of DNA from normal breast 
tissue – optimization for genome wide array analyses. BMC Res Notes 2011; 4:69. 
Absenger Y, Hess-Stumpp H, Kreft B, Kratzschmar J, Haendler B, Schutze N, Regidor 
PA, Winterhager E. Cyr61, a deregulated gene in endometriosis. Mol Hum Reprod 
2004; 10:399–407. 
Adachi S, Tajima A, Quan J, Haino K, Yoshihara K, Masuzaki H, Katabuchi H, Ikuma 
K, Suginami H, Nishida N, Kuwano R, Okazaki Y, Kawamura Y, Sasaki T, 
Tokunaga K, Inoue I, Tanaka K. Meta-analysis of genome-wide association scans 
for genetic susceptibility to endometriosis in Japanese population. J Hum Genet 
2010; 55:816–821. 
Aghajanova L, Giudice LC. Molecular evidence for differences in endometrium in 
severe versus mild endometriosis. Reprod Sci 2011; 18:229–251. 
Albertsen HM, Chettier R, Farrington P, Ward K. Genome-wide association study link 
novel loci to endometriosis. PLoS One 2013; 8:e58257. 
Altmae S, Esteban FJ, Stavreus-Evers A, Simon C, Giudice L, Lessey BA, Horcajadas 
JA, Macklon NS, D’Hooghe T, Campoy C, Fauser BC, Salamonsen LA, Salumets 
A. Guidelines for the design, analysis and interpretation of ‘omics’ data: focus on 
human endometrium. Hum Reprod Update 2014; 20:12–28. 
Anaf V, Simon P, Fayt I, Noel J. Smooth muscles are frequent components of endo-
metriotic lesions. Hum Reprod 2000; 15:767–771. 
Aragon AC, Kopf PG, Campen MJ, Huwe JK, Walker MK. In utero and lactational 
2,3,7,8-tetrachlorodibenzo-p-dioxin exposure: effects on fetal and adult cardiac gene 
expression and adult cardiac and renal morphology. Toxicol Sci 2008; 101:321–330. 
Arimoto T, Katagiri T, Oda K, Tsunoda T, Yasugi T, Osuga Y, Yoshikawa H, Nishii O, 
Yano T, Taketani Y, Nakamura Y. Genome-wide cDNA microarray analysis of 
gene-expression profiles involved in ovarian endometriosis. Int J Oncol 2003; 
22:551–560. 
Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, 
Irizarry RA. Minfi: a flexible and comprehensive Bioconductor package for the 
analysis of Infinium DNA methylation microarrays. Bioinformatics 2014; 30:1363–
1369. 
ASRM. Revised American Society for Reproductive Medicine classification of endo-
metriosis: 1996. Fertil Steril 1997; 67:817–821. 
Banno K, Yanokura M, Kisu I, Yamagami W, Susumu N, Aoki D. MicroRNAs in endo-
metrial cancer. Int J Clin Oncol 2013; 18:186–192. 
Barcena de Arellano ML, Mechsner S. The peritoneum – an important factor for patho-
genesis and pain generation in endometriosis. J Mol Med (Berl) 2014; 92:595–602. 
Becker CM, Laufer MR, Stratton P, Hummelshoj L, Missmer SA, Zondervan KT, 
Adamson GD. World Endometriosis Research Foundation Endometriosis Phenome 
and Biobanking Harmonisation Project: I. Surgical phenotype data collection in 
endometriosis research. Fertil Steril 2014; 102:1211–1222. 
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, 
Boehm JS, Dobson J, Urashima M et al.,. The landscape of somatic copy-number 
alteration across human cancers. Nature 2010; 463:899–905. 
Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16:6–21. 
64 
Borghese B, Barbaux S, Mondon F, Santulli P, Pierre G, Vinci G, Chapron C, Vaiman D. 
Research resource: genome-wide profiling of methylated promoters in endometriosis 
reveals a subtelomeric location of hypermethylation. Mol Endocrinol 2010; 
24:1872–1885. 
Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop – a motor of cellular plasticity 
in development and cancer? EMBO Rep 2010; 11:670–677. 
Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, Goodall GJ. 
A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 
family regulates epithelial-mesenchymal transition. Cancer Res 2008; 68:7846–
7854. 
Braza-Boils A, Mari-Alexandre J, Gilabert J, Sanchez-Izquierdo D, Espana F, Estelles A, 
Gilabert-Estelles J. MicroRNA expression profile in endometriosis: its relation to 
angiogenesis and fibrinolytic factors. Hum Reprod 2014; 29:978–988. 
Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil 
Steril 2012; 98:511–519. 
Burney RO, Hamilton AE, Aghajanova L, Vo KC, Nezhat CN, Lessey BA, Giudice LC. 
MicroRNA expression profiling of eutopic secretory endometrium in women with 
versus without endometriosis. Mol Hum Reprod 2009; 15:625–631. 
Burney RO, Talbi S, Hamilton AE, Vo KC, Nyegaard M, Nezhat CR, Lessey BA, 
Giudice LC. Gene expression analysis of endometrium reveals progesterone resistance 
and candidate susceptibility genes in women with endometriosis. Endocrinology 
2007; 148:3814–3826. 
Canis M, Bourdel N, Houlle C, Gremeau AS, Botchorishvili R, Matsuzaki S. Endo-
metriosis may not be a chronic disease: an alternative theory offering more opti-
mistic prospects for our patients. Fertil Steril 2016; 105:32–34. 
Carson DD, Lagow E, Thathiah A, Al-Shami R, Farach-Carson MC, Vernon M, Yuan L, 
Fritz MA, Lessey B. Changes in gene expression during the early to mid-luteal 
(receptive phase) transition in human endometrium detected by high-density 
microarray screening. Mol Hum Reprod 2002; 8:871–879. 
Catalano RD, Wilson MR, Boddy SC, Jabbour HN. Comprehensive expression analysis 
of prostanoid enzymes and receptors in the human endometrium across the 
menstrual cycle. Mol Hum Reprod 2011; 17:182–192. 
Chettier R, Ward K, Albertsen HM. Endometriosis is associated with rare copy number 
variants. PLoS One 2014; 9:e103968. 
Colella S, Yau C, Taylor JM, Mirza G, Butler H, Clouston P, Bassett AS, Seller A, 
Holmes CC, Ragoussis J. QuantiSNP: an Objective Bayes Hidden-Markov Model to 
detect and accurately map copy number variation using SNP genotyping data. 
Nucleic Acids Res 2007; 35:2013–2025. 
Cramer DW, Missmer SA. The epidemiology of endometriosis. Ann N Y Acad Sci 2002; 
955:11–22; discussion 34–16, 396–406. 
Creighton CJ, Benham AL, Zhu H, Khan MF, Reid JG, Nagaraja AK, Fountain MD, 
Dziadek O, Han D, Ma L, Kim J, Hawkins SM, Anderson ML, Matzuk MM, 
Gunaratne PH. Discovery of novel microRNAs in female reproductive tract using 
next generation sequencing. PLoS One 2010; 5:e9637. 
Crispi S, Piccolo MT, D’Avino A, Donizetti A, Viceconte R, Spyrou M, Calogero RA, 
Baldi A, Signorile PG. Transcriptional profiling of endometriosis tissues identifies 
genes related to organogenesis defects. J Cell Physiol 2013; 228:1927–1934. 
65 
Cummings M, McGinley CV, Wilkinson N, Field SL, Duffy SR, Orsi NM. A robust 
RNA integrity-preserving staining protocol for laser capture microdissection of 
endometrial cancer tissue. Anal Biochem 2011; 416:123–125. 
D’Hooghe TM, Bambra CS, Cornillie FJ, Isahakia M, Koninckx PR. Prevalence and 
laparoscopic appearance of spontaneous endometriosis in the baboon (Papio anubis, 
Papio cynocephalus). Biol Reprod 1991; 45:411–416. 
Diaz-Gimeno P, Horcajadas JA, Martinez-Conejero JA, Esteban FJ, Alama P, Pellicer 
A, Simon C. A genomic diagnostic tool for human endometrial receptivity based on 
the transcriptomic signature. Fertil Steril 2011; 95:50–60, 60 e51–15. 
Dunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D’Hooghe T, De Bie B, 
Heikinheimo O, Horne AW, Kiesel L, Nap A, Prentice A, Saridogan E, Soriano D, 
Nelen W. ESHRE guideline: management of women with endometriosis. Hum 
Reprod 2014; 29:400–412. 
Dyson MT, Roqueiro D, Monsivais D, Ercan CM, Pavone ME, Brooks DC, Kakinuma 
T, Ono M, Jafari N, Dai Y, Bulun SE. Genome-wide DNA methylation analysis 
predicts an epigenetic switch for GATA factor expression in endometriosis. PLoS 
Genet 2014; 10:e1004158. 
Eggers JC, Martino V, Reinbold R, Schafer SD, Kiesel L, Starzinski-Powitz A, 
Schuring AN, Kemper B, Greve B, Gotte M. microRNA miR-200b affects proli-
feration, invasiveness and stemness of endometriotic cells by targeting ZEB1, ZEB2 
and KLF4. Reprod Biomed Online 2016;  
Eyster KM, Klinkova O, Kennedy V, Hansen KA. Whole genome deoxyribonucleic 
acid microarray analysis of gene expression in ectopic versus eutopic endometrium. 
Fertil Steril 2007; 88:1505–1533. 
Fassbender A, Rahmioglu N, Vitonis AF, Vigano P, Giudice LC, D’Hooghe TM, Hum-
melshoj L, Adamson GD, Becker CM, Missmer SA, Zondervan KT. World Endo-
metriosis Research Foundation Endometriosis Phenome and Biobanking Harmo-
nisation Project: IV. Tissue collection, processing, and storage in endometriosis 
research. Fertil Steril 2014; 10:1244–1253. 
Fassbender A, Verbeeck N, Bornigen D, Kyama CM, Bokor A, Vodolazkaia A, Peeraer K, 
Tomassetti C, Meuleman C, Gevaert O, Van de Plas R, Ojeda F, De Moor B, 
Moreau Y, Waelkens E, D’Hooghe TM. Combined mRNA microarray and pro-
teomic analysis of eutopic endometrium of women with and without endometriosis. 
Hum Reprod 2012; 27:2020–2029. 
Fayez JA, Vogel MF. Comparison of different treatment methods of endometriomas by 
laparoscopy. Obstet Gynecol 1991; 78:660–665. 
Fernando S, Soh PQ, Cooper M, Evans S, Reid G, Tsaltas J, Rombauts L. Reliability of 
visual diagnosis of endometriosis. J Minim Invasive Gynecol 2013; 20:783–789. 
Filigheddu N, Gregnanin I, Porporato PE, Surico D, Perego B, Galli L, Patrignani C, 
Graziani A, Surico N. Differential expression of microRNAs between eutopic and 
ectopic endometrium in ovarian endometriosis. J Biomed Biotechnol 2010; 
2010:369549. 
Furukawa J, Inoue K, Maeda J, Yasujima T, Ohta K, Kanai Y, Takada T, Matsuo H, 
Yuasa H. Functional identification of SLC43A3 as an equilibrative nucleobase 
transporter involved in purine salvage in mammals. Sci Rep 2015; 5:15057. 
Gilabert-Estelles J, Braza-Boils A, Ramon LA, Zorio E, Medina P, Espana F, Estelles 
A. Role of microRNAs in gynecological pathology. Curr Med Chem 2012; 
19:2406–2413. 
Giudice LC. Clinical practice. Endometriosis. N Engl J Med 2010; 362:2389–2398. 
5 
66 
Gogusev J, Bouquet de Joliniere J, Telvi L, Doussau M, du Manoir S, Stojkoski A, 
Levardon M. Detection of DNA copy number changes in human endometriosis by 
comparative genomic hybridization. Hum Genet 1999; 105:444–451. 
Grandi G, Toss A, Cortesi L, Botticelli L, Volpe A, Cagnacci A. The Association 
between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting 
Ovulation and Menstruation during Reproductive Life. Biomed Res Int 2015; 
2015:751571. 
Guo SW, Wu Y, Strawn E, Basir Z, Wang Y, Halverson G, Montgomery K, Kajdacsy-
Balla A. Genomic alterations in the endometrium may be a proximate cause for 
endometriosis. Eur J Obstet Gynecol Reprod Biol 2004; 116:89–99. 
Haouzi D, Assou S, Mahmoud K, Tondeur S, Reme T, Hedon B, De Vos J, Hamamah S. 
Gene expression profile of human endometrial receptivity: comparison between 
natural and stimulated cycles for the same patients. Hum Reprod 2009; 24:1436–
1445. 
Hawkins SM, Creighton CJ, Han DY, Zariff A, Anderson ML, Gunaratne PH, Matzuk 
MM. Functional microRNA involved in endometriosis. Mol Endocrinol 2011; 
25:821–832. 
Heberle H, Meirelles GV, da Silva FR, Telles GP, Minghim R. InteractiVenn: a web-
based tool for the analysis of sets through Venn diagrams. BMC Bioinformatics 
2015; 16:169. 
Hever A, Roth RB, Hevezi P, Marin ME, Acosta JA, Acosta H, Rojas J, Herrera R, 
Grigoriadis D, White E, Conlon PJ, Maki RA, Zlotnik A. Human endometriosis is 
associated with plasma cells and overexpression of B lymphocyte stimulator. Proc 
Natl Acad Sci U S A 2007; 104:12451–12456. 
Hill L, Browne G, Tulchinsky E. ZEB/miR-200 feedback loop: at the crossroads of 
signal transduction in cancer. Int J Cancer 2013; 132:745–754. 
Houshdaran S, Zelenko Z, Irwin JC, Giudice LC. Human endometrial DNA methylome 
is cycle-dependent and is associated with gene expression regulation. Mol Endo-
crinol 2014; 28:1118–1135. 
Hsu AL, Khachikyan I, Stratton P. Invasive and noninvasive methods for the diagnosis 
of endometriosis. Clin Obstet Gynecol 2010; 53:413–419. 
Hu S, Yao G, Wang Y, Xu H, Ji X, He Y, Zhu Q, Chen Z, Sun Y. Transcriptomic 
changes during the pre-receptive to receptive transition in human endometrium 
detected by RNA-Seq. J Clin Endocrinol Metab 2014; 99:E2744–2753. 
Hu WP, Tay SK, Zhao Y. Endometriosis-specific genes identified by real-time reverse 
transcription-polymerase chain reaction expression profiling of endometriosis versus 
autologous uterine endometrium. J Clin Endocrinol Metab 2006; 91:228–238. 
Kao LC, Germeyer A, Tulac S, Lobo S, Yang JP, Taylor RN, Osteen K, Lessey BA, 
Giudice LC. Expression profiling of endometrium from women with endometriosis 
reveals candidate genes for disease-based implantation failure and infertility. Endo-
crinology 2003; 144:2870–2881. 
Karhu R, Kahkonen M, Kuukasjarvi T, Pennanen S, Tirkkonen M, Kallioniemi O. 
Quality control of CGH: impact of metaphase chromosomes and the dynamic range 
of hybridization. Cytometry 1997; 28:198–205. 
Kato K, Yoshimoto M, Adachi S, Yamayoshi A, Arima T, Asanoma K, Kyo S, Naka-
hata T, Wake N. Characterization of side-population cells in human normal endo-
metrium. Hum Reprod 2007; 22:1214–1223. 
67 
Kennedy S, Bergqvist A, Chapron C, D’Hooghe T, Dunselman G, Greb R, Hummelshoj L, 
Prentice A, Saridogan E. ESHRE guideline for the diagnosis and treatment of endo-
metriosis. Hum Reprod 2005; 20:2698–2704. 
Khan MA, Sengupta J, Mittal S, Ghosh D. Genome-wide expressions in autologous 
eutopic and ectopic endometrium of fertile women with endometriosis. Reprod Biol 
Endocrinol 2012; 10:84. 
Kobayashi H, Yamashita Y, Iwase A, Yoshikawa Y, Yasui H, Kawai Y, Uchida K, Uno N, 
Akatsuka S, Takahashi T, Kikkawa F, Toyokuni S. The ferroimmunomodulatory 
role of ectopic endometriotic stromal cells in ovarian endometriosis. Fertil Steril 
2012; 98:415–422 e411–412. 
Koninckx PR, Kennedy SH, Barlow DH. Endometriotic disease: the role of peritoneal 
fluid. Hum Reprod Update 1998; 4:741–751. 
Konno R, Yamada-Okabe H, Fujiwara H, Uchiide I, Shibahara H, Ohwada M, Ihara T, 
Sugamata M, Suzuki M. Role of immunoreactions and mast cells in pathogenesis of 
human endometriosis – morphologic study and gene expression analysis. Hum Cell 
2003; 16:141–149. 
Korpal M, Kang Y. The emerging role of miR-200 family of microRNAs in epithelial-
mesenchymal transition and cancer metastasis. RNA Biol 2008; 5:115–119. 
Krjutskov K, Katayama S, Saare M, Vera-Rodriguez M, Lubenets D, Samuel K, Laisk-
Podar T, Teder H, Einarsdottir E, Salumets A, Kere J. Single-cell transcriptome 
analysis of endometrial tissue. Hum Reprod 2016;  
Laudanski P, Charkiewicz R, Kuzmicki M, Szamatowicz J, Charkiewicz A, Niklinski J. 
MicroRNAs expression profiling of eutopic proliferative endometrium in women 
with ovarian endometriosis. Reprod Biol Endocrinol 2013; 11:78. 
Laudanski P, Charkiewicz R, Tolwinska A, Szamatowicz J, Charkiewicz A, Niklinski J. 
Profiling of Selected MicroRNAs in Proliferative Eutopic Endometrium of Women 
with Ovarian Endometriosis. Biomed Res Int 2015; 2015:760698. 
Lebovic DI, Baldocchi RA, Mueller MD, Taylor RN. Altered expression of a cell-cycle 
suppressor gene, Tob-1, in endometriotic cells by cDNA array analyses. Fertil Steril 
2002; 78:849–854. 
Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 
2002; 18:1427–1431. 
Li W, Olivier M. Current analysis platforms and methods for detecting copy number 
variation. Physiol Genomics 2013; 45:1–16. 
Li X, Zhang Y, Zhao L, Wang L, Wu Z, Mei Q, Nie J, Li Y, Fu X, Wang X, Meng Y, 
Han W. Whole-exome sequencing of endometriosis identifies frequent alterations in 
genes involved in cell adhesion and chromatin-remodeling complexes. Hum Mol 
Genet 2014; 23:6008–6021. 
Lize M, Klimke A, Dobbelstein M. MicroRNA-449 in cell fate determination. Cell 
Cycle 2011; 10:2874–2882. 
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402–408. 
Lokk K, Modhukur V, Rajashekar B, Martens K, Magi R, Kolde R, Koltsina M, Nilsson 
TK, Vilo J, Salumets A, Tonisson N. DNA methylome profiling of human tissues 
identifies global and tissue-specific methylation patterns. Genome Biol 2014; 15:r54. 
Ludwig H, Spornitz UM. Microarchitecture of the human endometrium by scanning 
electron microscopy: menstrual desquamation and remodeling. Ann N Y Acad Sci 
1991; 622:28–46. 
68 
Macer ML, Taylor HS. Endometriosis and infertility: a review of the pathogenesis and 
treatment of endometriosis-associated infertility. Obstet Gynecol Clin North Am 
2012; 39:535–549. 
Marchand E, Hequet D, Thoury A, Barranger E. Malignant transformation of superficial 
peritoneal endometriosis lesion. BMJ Case Rep 2013; 2013:007730. 
Mazur K (2005) Diagnosis of Endometrial Biopsies and Curettings. A practical 
Approach. Second edn. Springer,  
Matsuzaki S, Canis M, Vaurs-Barriere C, Boespflug-Tanguy O, Dastugue B, Mage G. 
DNA microarray analysis of gene expression in eutopic endometrium from patients 
with deep endometriosis using laser capture microdissection. Fertil Steril 2005; 84 
Suppl 2:1180–1190. 
Matsuzaki S, Canis M, Vaurs-Barriere C, Pouly JL, Boespflug-Tanguy O, Penault-
Llorca F, Dechelotte P, Dastugue B, Okamura K, Mage G. DNA microarray analysis 
of gene expression profiles in deep endometriosis using laser capture micro-
dissection. Mol Hum Reprod 2004; 10:719–728. 
May KE, Conduit-Hulbert SA, Villar J, Kirtley S, Kennedy SH, Becker CM. Peripheral 
biomarkers of endometriosis: a systematic review. Hum Reprod Update 2010; 
16:651–674. 
Mercer TR, Mattick JS. Structure and function of long noncoding RNAs in epigenetic 
regulation. Nat Struct Mol Biol 2013; 20:300–307. 
Moen MH, Halvorsen TB. Histologic confirmation of endometriosis in different 
peritoneal lesions. Acta Obstet Gynecol Scand 1992; 71:337–342. 
Morris AP, Voight BF, Teslovich TM, Ferreira T, Segre AV, Steinthorsdottir V, 
Strawbridge RJ, Khan H, Grallert H, Mahajan A et al.,. Large-scale association 
analysis provides insights into the genetic architecture and pathophysiology of type 
2 diabetes. Nat Genet 2012; 44:981–990. 
Muzii L, Bianchi A, Bellati F, Cristi E, Pernice M, Zullo MA, Angioli R, Panici PB. 
Histologic analysis of endometriomas: what the surgeon needs to know. Fertil Steril 
2007; 87:362–366. 
Naqvi H, Ilagan Y, Krikun G, Taylor HS. Altered Genome-Wide Methylation in Endo-
metriosis. Reprod Sci 2014; 1237–1243. 
Nasu K, Kawano Y, Tsukamoto Y, Takano M, Takai N, Li H, Furukawa Y, Abe W, 
Moriyama M, Narahara H. Aberrant DNA methylation status of endometriosis: 
epigenetics as the pathogenesis, biomarker and therapeutic target. J Obstet Gynaecol 
Res 2011; 37:683–695. 
Nishizawa H, Imanishi S, Manabe N. Effects of exposure in utero to bisphenol a on the 
expression of aryl hydrocarbon receptor, related factors, and xenobiotic meta-
bolizing enzymes in murine embryos. J Reprod Dev 2005; 51:593–605. 
Nisolle M, Donnez J. Peritoneal endometriosis, ovarian endometriosis, and adenomyotic 
nodules of the rectovaginal septum are three different entities. Fertil Steril 1997; 
68:585–596. 
Nyholt DR, Low SK, Anderson CA, Painter JN, Uno S, Morris AP, MacGregor S, 
Gordon SD, Henders AK, Martin NG, Attia J, Holliday EG, McEvoy M, Scott RJ, 
Kennedy SH, Treloar SA, Missmer SA, Adachi S, Tanaka K, Nakamura Y, 
Zondervan KT, Zembutsu H, Montgomery GW. Genome-wide association meta-
analysis identifies new endometriosis risk loci. Nat Genet 2012; 44:1355–1359. 
Ohlsson Teague EM, Van der Hoek KH, Van der Hoek MB, Perry N, Wagaarachchi P, 
Robertson SA, Print CG, Hull LM. MicroRNA-regulated pathways associated with 
endometriosis. Mol Endocrinol 2009; 23:265–275. 
69 
Oral E, Ilvan S, Tustas E, Korbeyli B, Bese T, Demirkiran F, Arvas M, Kosebay D. 
Prevalence of endometriosis in malignant epithelial ovary tumours. Eur J Obstet 
Gynecol Reprod Biol 2003; 109:97–101. 
Ozdemir V, Suarez-Kurtz G, Stenne R, Somogyi AA, Someya T, Kayaalp SO, Kolker E. 
Risk assessment and communication tools for genotype associations with multi-
factorial phenotypes: the concept of “edge effect” and cultivating an ethical bridge 
between omics innovations and society. Omics 2009; 13:43–61. 
Pagliardini L, Gentilini D, Vigano P, Panina-Bordignon P, Busacca M, Candiani M, Di 
Blasio AM. An Italian association study and meta-analysis with previous GWAS 
confirm WNT4, CDKN2BAS and FN1 as the first identified susceptibility loci for 
endometriosis. J Med Genet 2013; 50:43–46. 
Painter JN, Anderson CA, Nyholt DR, Macgregor S, Lin J, Lee SH, Lambert A, Zhao 
ZZ, Roseman F, Guo Q, Gordon SD, Wallace L, Henders AK, Visscher PM, Kraft 
P, Martin NG, Morris AP, Treloar SA, Kennedy SH, Missmer SA, Montgomery 
GW, Zondervan KT. Genome-wide association study identifies a locus at 7p15.2 
associated with endometriosis. Nat Genet 2011; 43:51–54. 
Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial 
phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. 
Genes Dev 2008; 22:894–907. 
Parrish RR, Day JJ, Lubin FD. Direct bisulfite sequencing for examination of DNA 
methylation with gene and nucleotide resolution from brain tissues. Curr Protoc 
Neurosci 2012; Chapter 7:Unit 7 24. 
Pinto D, Marshall C, Feuk L, Scherer SW. Copy-number variation in control population 
cohorts. Hum Mol Genet 2007; 16 Spec No. 2:R168–173. 
Ponnampalam AP, Weston GC, Trajstman AC, Susil B, Rogers PA. Molecular classi-
fication of human endometrial cycle stages by transcriptional profiling. Mol Hum 
Reprod 2004; 10:879–893. 
Potlog-Nahari C, Feldman AL, Stratton P, Koziol DE, Segars J, Merino MJ, Nieman 
LK. CD10 immunohistochemical staining enhances the histological detection of 
endometriosis. Fertil Steril 2004; 82:86–92. 
Rahmioglu N, Fassbender A, Vitonis AF, Tworoger SS, Hummelshoj L, D’Hooghe TM, 
Adamson GD, Giudice LC, Becker CM, Zondervan KT, Missmer SA. World 
Endometriosis Research Foundation Endometriosis Phenome and Biobanking 
Harmonization Project: III. Fluid biospecimen collection, processing, and storage in 
endometriosis research. Fertil Steril 2014a;  
Rahmioglu N, Nyholt DR, Morris AP, Missmer SA, Montgomery GW, Zondervan KT. 
Genetic variants underlying risk of endometriosis: insights from meta-analysis of 
eight genome-wide association and replication datasets. Hum Reprod Update 2014b; 
20:702–716. 
Rakhila H, Carli C, Daris M, Lemyre M, Leboeuf M, Akoum A. Identification of 
multiple and distinct defects in prostaglandin biosynthetic pathways in eutopic and 
ectopic endometrium of women with endometriosis. Fertil Steril 2013; 100:1650–
1659 e1651–1652. 
Rizner TL. Enzymes of the AKR1B and AKR1C Subfamilies and Uterine Diseases. 
Front Pharmacol 2012; 3:34. 
Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for dif-
ferential expression analysis of digital gene expression data. Bioinformatics 2010; 
26:139–140. 
5 
70 
Rogers PA, D’Hooghe TM, Fazleabas A, Giudice LC, Montgomery GW, Petraglia F, 
Taylor RN. Defining future directions for endometriosis research: workshop report 
from the 2011 World Congress of Endometriosis In Montpellier, France. Reprod Sci 
2013; 20:483–499. 
Romero-Perez L, Lopez-Garcia MA, Diaz-Martin J, Biscuola M, Castilla MA, Tafe LJ, 
Garg K, Oliva E, Matias-Guiu X, Soslow RA, Palacios J. ZEB1 overexpression 
associated with E-cadherin and microRNA-200 downregulation is characteristic of 
undifferentiated endometrial carcinoma. Mod Pathol 2013;  
Sampson JA. Metastatic or Embolic Endometriosis, due to the Menstrual Dissemination 
of Endometrial Tissue into the Venous Circulation. Am J Pathol 1927; 3:93–110 
143. 
Sanfilippo JS, Wakim NG, Schikler KN, Yussman MA. Endometriosis in association 
with uterine anomaly. Am J Obstet Gynecol 1986; 154:39–43. 
Sapkota Y, Fassbender A, Bowdler L, Fung JN, Peterse D, O D, Montgomery GW, 
Nyholt DR, D’Hooghe TM. Independent Replication and Meta-Analysis for Endo-
metriosis Risk Loci. Twin Res Hum Genet 2015; 1–8. 
Sasson IE, Taylor HS. Stem cells and the pathogenesis of endometriosis. Ann N Y Acad 
Sci 2008; 1127:106–115. 
Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, Maner S, Massa H, 
Walker M, Chi M, Navin N, Lucito R, Healy J, Hicks J, Ye K, Reiner A, Gilliam 
TC, Trask B, Patterson N, Zetterberg A, Wigler M. Large-scale copy number 
polymorphism in the human genome. Science 2004; 305:525–528. 
Sha AG, Liu JL, Jiang XM, Ren JZ, Ma CH, Lei W, Su RW, Yang ZM. Genome-wide 
identification of micro-ribonucleic acids associated with human endometrial re-
ceptivity in natural and stimulated cycles by deep sequencing. Fertil Steril 2011; 
96:150–155 e155. 
Sherwin JR, Sharkey AM, Mihalyi A, Simsa P, Catalano RD, D’Hooghe TM. Global 
gene analysis of late secretory phase, eutopic endometrium does not provide the 
basis for a minimally invasive test of endometriosis. Hum Reprod 2008; 23:1063–
1068. 
Shi XY, Gu L, Chen J, Guo XR, Shi YL. Downregulation of miR-183 inhibits apoptosis 
and enhances the invasive potential of endometrial stromal cells in endometriosis. 
Int J Mol Med 2014; 33:59–67. 
Signorile PG, Baldi A. Endometriosis: new concepts in the pathogenesis. Int J Biochem 
Cell Biol 2010a; 42:778–780. 
Signorile PG, Spugnini EP, Mita L, Mellone P, D’Avino A, Bianco M, Diano N, Caputo L, 
Rea F, Viceconte R, Portaccio M, Viggiano E, Citro G, Pierantoni R, Sica V, 
Vincenzi B, Mita DG, Baldi F, Baldi A. Pre-natal exposure of mice to bisphenol A 
elicits an endometriosis-like phenotype in female offspring. Gen Comp Endocrinol 
2010b; 168:318–325. 
Silveira CG, Abrao MS, Dias JA, Jr., Coudry RA, Soares FA, Drigo SA, Domingues 
MA, Rogatto SR. Common chromosomal imbalances and stemness-related protein 
expression markers in endometriotic lesions from different anatomical sites: the 
potential role of stem cells. Hum Reprod 2012; 27:3187–3197. 
Sinreih M, Anko M, Kene NH, Kocbek V, Rizner TL. Expression of AKR1B1, 
AKR1C3 and other genes of prostaglandin F2alpha biosynthesis and action in 
ovarian endometriosis tissue and in model cell lines. Chem Biol Interact 2015; 
234:320–331. 
71 
Stankiewicz P, Lupski JR. Structural variation in the human genome and its role in 
disease. Annu Rev Med 2010; 61:437–455. 
Stegmann BJ, Sinaii N, Liu S, Segars J, Merino M, Nieman LK, Stratton P. Using 
location, color, size, and depth to characterize and identify endometriosis lesions in 
a cohort of 133 women. Fertil Steril 2008; 89:1632–1636. 
Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne N, Redon R, Bird 
CP, de Grassi A, Lee C, Tyler-Smith C, Carter N, Scherer SW, Tavare S, Deloukas P, 
Hurles ME, Dermitzakis ET. Relative impact of nucleotide and copy number 
variation on gene expression phenotypes. Science 2007; 315:848–853. 
Stratton P, Winkel C, Premkumar A, Chow C, Wilson J, Hearns-Stokes R, Heo S, 
Merino M, Nieman LK. Diagnostic accuracy of laparoscopy, magnetic resonance 
imaging, and histopathologic examination for the detection of endometriosis. Fertil 
Steril 2003; 79:1078–1085. 
Stuart RO, Pavlova A, Beier D, Li Z, Krijanovski Y, Nigam SK. EEG1, a putative 
transporter expressed during epithelial organogenesis: comparison with embryonic 
transporter expression during nephrogenesis. Am J Physiol Renal Physiol 2001; 
281:F1148–1156. 
Sumathi VP, McCluggage WG. CD10 is useful in demonstrating endometrial stroma at 
ectopic sites and in confirming a diagnosis of endometriosis. J Clin Pathol 2002; 
55:391–392. 
Sun PR, Jia SZ, Lin H, Leng JH, Lang JH. Genome-wide profiling of long noncoding 
ribonucleic acid expression patterns in ovarian endometriosis by microarray. Fertil 
Steril 2014; 101:1038–1046 e1037. 
Sundqvist J, Xu H, Vodolazkaia A, Fassbender A, Kyama C, Bokor A, Gemzell-
Danielsson K, D’Hooghe TM, Falconer H. Replication of endometriosis-associated 
single-nucleotide polymorphisms from genome-wide association studies in a 
Caucasian population. Hum Reprod 2013; 28:835–839. 
Zafrakas M, Tarlatzis BC, Streichert T, Pournaropoulos F, Wolfle U, Smeets SJ, Wittek 
B, Grimbizis G, Brakenhoff RH, Pantel K, Bontis J, Gunes C. Genome-wide micro-
array gene expression, array-CGH analysis, and telomerase activity in advanced 
ovarian endometriosis: a high degree of differentiation rather than malignant 
potential. Int J Mol Med 2008; 21:335–344. 
Zhang B, Zhou Y, Lin N, Lowdon RF, Hong C, Nagarajan RP, Cheng JB, Li D, Stevens M, 
Lee HJ et al.,. Functional DNA methylation differences between tissues, cell types, 
and across individuals discovered using the M&M algorithm. Genome Res 2013; 
23:1522–1540. 
Talbi S, Hamilton AE, Vo KC, Tulac S, Overgaard MT, Dosiou C, Le Shay N, Nezhat 
CN, Kempson R, Lessey BA, Nayak NR, Giudice LC. Molecular phenotyping of 
human endometrium distinguishes menstrual cycle phases and underlying biological 
processes in normo-ovulatory women. Endocrinology 2006; 147:1097–1121. 
Talseth-Palmer BA, Bowden NA, Hill A, Meldrum C, Scott RJ. Whole genome 
amplification and its impact on CGH array profiles. BMC Res Notes 2008; 1:56. 
Tamaresis JS, Irwin JC, Goldfien GA, Rabban JT, Burney RO, Nezhat C, DePaolo LV, 
Giudice LC. Molecular Classification of Endometriosis and Disease Stage Using 
High-Dimensional Genomic Data. Endocrinology 2014; en20141490. 
Teo SM, Ku CS, Naidoo N, Hall P, Chia KS, Salim A, Pawitan Y. A population-based 
study of copy number variants and regions of homozygosity in healthy Swedish 
individuals. J Hum Genet 2011; 56:524–533. 
72 
Torres A, Torres K, Wdowiak P, Paszkowski T, Maciejewski R. Selection and vali-
dation of endogenous controls for microRNA expression studies in endometrioid 
endometrial cancer tissues. Gynecol Oncol 2013; 130:588–594. 
Uno S, Zembutsu H, Hirasawa A, Takahashi A, Kubo M, Akahane T, Aoki D, 
Kamatani N, Hirata K, Nakamura Y. A genome-wide association study identifies 
genetic variants in the CDKN2BAS locus associated with endometriosis in 
Japanese. Nat Genet 2010; 42:707–710. 
Walter AJ, Hentz JG, Magtibay PM, Cornella JL, Magrina JF. Endometriosis: corre-
lation between histologic and visual findings at laparoscopy. Am J Obstet Gynecol 
2001; 184:1407–1411; discussion 1411–1403. 
Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SF, Hakonarson H, Bucan M. 
PennCNV: an integrated hidden Markov model designed for high-resolution copy 
number variation detection in whole-genome SNP genotyping data. Genome Res 
2007; 17:1665–1674. 
Wang Y, Li Y, Yang Z, Liu K, Wang D. Genome-Wide Microarray Analysis of Long 
Non-Coding RNAs in Eutopic Secretory Endometrium with Endometriosis. Cell 
Physiol Biochem 2015; 37:2231–2245. 
Wanyonyi SZ, Sequeira E, Mukono SG. Correlation between laparoscopic and histo-
pathologic diagnosis of endometriosis. Int J Gynaecol Obstet 2011; 115:273–276. 
Veiga-Castelli LC, Silva JC, Meola J, Ferriani RA, Yoshimoto M, Santos SA, Squire 
JA, Martelli L. Genomic alterations detected by comparative genomic hybridization 
in ovarian endometriomas. Braz J Med Biol Res 2010; 43:799–805. 
Visscher PM, Brown MA, McCarthy MI, Yang J. Five years of GWAS discovery. Am J 
Hum Genet 2012; 90:7–24. 
Vodolazkaia A, El-Aalamat Y, Popovic D, Mihalyi A, Bossuyt X, Kyama CM, 
Fassbender A, Bokor A, Schols D, Huskens D, Meuleman C, Peeraer K, Tomassetti 
C, Gevaert O, Waelkens E, Kasran A, De Moor B, D’Hooghe TM. Evaluation of a 
panel of 28 biomarkers for the non-invasive diagnosis of endometriosis. Hum 
Reprod 2012; 27:2698–2711. 
Vrba L, Garbe JC, Stampfer MR, Futscher BW. Epigenetic regulation of normal human 
mammary cell type-specific miRNAs. Genome Res 2011; 21:2026–2037. 
Wu Y, Kajdacsy-Balla A, Strawn E, Basir Z, Halverson G, Jailwala P, Wang Y, Wang X, 
Ghosh S, Guo SW. Transcriptional characterizations of differences between eutopic 
and ectopic endometrium. Endocrinology 2006a; 147:232–246. 
Wu Y, Strawn E, Basir Z, Wang Y, Halverson G, Jailwala P, Guo SW. Genomic 
alterations in ectopic and eutopic endometria of women with endometriosis. Gynecol 
Obstet Invest 2006b; 62:148–159. 
Yamagata Y, Nishino K, Takaki E, Sato S, Maekawa R, Nakai A, Sugino N. Genome-
wide DNA methylation profiling in cultured eutopic and ectopic endometrial stromal 
cells. PLoS One 2014; 9:e83612. 
Yang W, Zhang Y, Fu F, Li R. High-resolution array-comparative genomic hybri-
dization profiling reveals 20q13.33 alterations associated with ovarian endo-
metriosis. Gynecol Endocrinol 2013; 29:603–607. 
Young VJ, Brown JK, Saunders PT, Horne AW. The role of the peritoneum in the 
pathogenesis of endometriosis. Hum Reprod Update 2013; 19:558–569. 
 
  
73 
ACKNOWLEDGEMENTS 
This thesis is a condensation of studies that are conducted with the help and 
support of many contributors and various organizations that all deserve to be 
acknowledged. These studies were carried out at the Department of Obstetrics 
and Gynecology at the University of Tartu and the Competence Centre on 
Health Technologies, and were supported by the Estonian Ministry of Education 
and Research, the European Regional Development Fund through the Estonian 
Centre of Excellence in Genomics, Enterprise Estonia and FP7 Marie Curie 
Industry-Academia Partnerships and Pathway grant (SARM). Moreover, none 
of these projects could have been carried out without the help of women willing 
to participate, the medical personnel of the Tartu University Hospital’s 
Women’s Clinic, Nova Vita Clinic and Elite Clinic who helped with patient 
enrolment and collection of tissue samples. Thank you all!  
An African proverb says: “If you want to go fast, go alone. If you want to go 
far, go together.” I have been extremely lucky to have so many good friends and 
colleagues share this exciting scientific journey with me. Thank you all my 
friends and colleges, without your help and support I would be still on the road 
and would have never reached so far! I would like to express my sincerest 
gratitude to: 
– supervisor Professor Andres Salumets for guiding me to the field of 
reproductive genetics, his unlimited enthusiasm and original ideas. 
– supervisor Professor Helle Karro for her valuable professional advice during 
my doctoral studies.  
– supervisor Maire Peters. There are no words that can express my gratitude 
and appreciation for her guidance and continuous support that kept me well 
motivated and on the right track. Thank you for your time, your friendship, 
encouragement and endless patience. 
– all my present and former colleagues from the CCHT who have contributed 
in many ways to the success of these studies. Thank you, Külli, Katrin, Triin, 
Triin L-P, Kristi, Signe, Anne Mari, Elo, Alar, Mariann, Esta, Jaak, Hardi, 
Annegrete, Kadri, Marina, Kaarel, Agne and Gerly for your professional 
advice and good company that made the working environment really 
enjoyable.  
– Triin L-P, who is the kindest person I’ve ever known. Thank you for your 
friendship, your sharp mind and willingness to always help with statistics 
and language corrections. 
– Kadri, Elo, Külli and Triin L-P for reviewing this thesis and providing 
constructive comments.  
– co-authors of the studies for their valuable contribution. Especially, I´m 
really grateful to persons who helped me with statistics and data analyses – 
Triin Laisk-Podar, Priit Palta, Jaak Simm, Tauno Metsalu, and Vijayachitra 
Modhukur.  
– reviewers Dr. Lili Milani and Dr. Kristiina Rull for their helpful comments. 
5 
74 
These acknowledgements would not be complete if I did not thank my parents, 
family and friends for their precious support. I am really grateful to my 
parents – Jüri and Rutt Lattik for their unconditional love, support and for 
always being there for me. Thank you! Also, I would like to express my 
gratitude to my parents in-law, Enn and Linda, for supporting and taking such a 
great care of me throughout these years and being wonderful grandparents to 
my kids. My dear friends Liia, Marju, Helle-Mai and Imbi thank you for 
fantastic meetings and great discussions. Heidi, thank you for being the best 
friend and always ready to help and listen. I really enjoy our long walks and 
great conversations. Last but not least, I truly acknowledge my husband Meelis 
for his endless patience and support throughout these years. I realize that the life 
together with a wife who is constantly hurrying, studying, working and 
travelling and with two little kids is not an easy task. Thank you for everything! 
Also, I’m very grateful to my nine-year old twins, Merille and Otomar, for 
spicing up my life in many different ways and for helping me to recognize the 
real priorities in life. 
  
  
 
 
  
PUBLICATIONS 
11  1
CURRICULUM VITAE 
Name:  Merli Saare 
Date of birth:  28.11.1976  
Citizenship:  Estonian  
Telephone:  +372 7330402 
E-mail:  merli.saare@ut.ee  
 
Education:  
2011–  University of Tartu, PhD studies in Medical Sciences  
2005–2008  University of Tartu, Faculty of Medicine, MSc in biomedicine 
2001–2005  University of Tartu, Faculty of Biology and Geography, BSc in 
molecular diagnostics, gene technology 
1993–1995  Hugo Treffner Gymnasium, secondary education 
 
Professional employment: 
2010–...  Competence Centre on Health Technologies; researcher  
2009–...  University of Tartu, Faculty of Medicine, Institute of Clinical 
medicine, Department of Obstetrics and Gynecology, researcher  
2008–2009  Estonian Biocentre; researcher  
2008  University of Tartu, Faculty of Biology and Geography, 
Institute of Molecular and Cell Biology; researcher  
 
Supervision: Kadri Madissoo, MSc degree in biomedicine, University of Tartu, 
2012, (sup) Merli Saare; Andres Salumets; Neeme Tõnisson, “DNA copy 
number alterations in women with endometriosis”. 
 
Publications:  
Krjutskov K, Katayama S, Saare M, Vera-Rodriguez M, Lubenets D, Samuel K, 
Laisk-Podar T, Teder H, Einarsdottir E, Salumets A, Kere J. Single-cell 
transcriptome analysis of endometrial tissue. Hum Reprod 2016.  
Saare M, Modhukur V, Suhorutshenko M, Rajashekar B, Rekker K, Soritsa D, 
Karro H, Soplepmann P, Soritsa A, Lindgren CM, Rahmioglu N, Drong A, 
Becker CM, Zondervan KT, Salumets A, Peters M. The influence of 
menstrual cycle and endometriosis on endometrial methylome. Clin Epi-
genetics 2016; 8:2. 
Rekker K, Saare M, Roost AM, Kaart T, Soritsa D, Karro H, Soritsa A, Simon C, 
Salumets A, Peters M. Circulating miR-200-family micro-RNAs have altered 
plasma levels in patients with endometriosis and vary with blood collection 
time. Fertil Steril 2015; 104:938–946 e932. 
Soritsa D, Saare M, Laisk-Podar T, Peters M, Soritsa A, Matt K, Karro H, 
Salumets A. Pregnancy rate in endometriosis patients according to the severity 
of the disease after using a combined approach of laparoscopy, GnRH agonist 
treatment and in vitro fertilization. Gynecol Obstet Invest 2015; 79:34–39 
112
Saare M, Rekker K, Laisk-Podar T, Soritsa D, Roost AM, Simm J, Velthut-
Meikas A, Samuel K, Metsalu T, Karro H, Soritsa A, Salumets A, Peters M. 
High-Throughput Sequencing Approach Uncovers the miRNome of Perito-
neal Endometriotic Lesions and Adjacent Healthy Tissues. PLoS One 2014; 
9:e112630. 
Rekker K, Saare M, Roost AM, Kubo AL, Zarovni N, Chiesi A, Salumets A, 
Peters M. Comparison of serum exosome isolation methods for microRNA 
profiling. Clin Biochem 2014; 47:135–138. 
Rekker K, Saare M, Roost AM, Salumets A, Peters M. Circulating microRNA 
Profile throughout the menstrual cycle. PLoS One 2013; 8:e81166. 
Altmae S, Reimand J, Hovatta O, Zhang P, Kere J, Laisk T, Saare M, Peters M, 
Vilo J, Stavreus-Evers A, Salumets A. Research resource: interactome of 
human embryo implantation: identification of gene expression pathways, 
regulation, and integrated regulatory networks. Mol Endocrinol 2012; 
26:203–217. 
Lamp M, Saare M, Kadastik U, Karro H, Salumets A, Uibo R, Peters M. 
Survivin promoter polymorphisms and autoantibodies in endometriosis. J 
Reprod Immunol 2012; 96:95–100. 
Saare M, Soritsa D, Vaidla K, Palta P, Remm M, Laan M, Karro H, Soritsa A, 
Salumets A, D’Hooghe T, Peters M. No evidence of somatic DNA copy 
number alterations in eutopic and ectopic endometrial tissue in endo-
metriosis. Hum Reprod 2012; 27:1857–1864. 
Saare M, Lamp M, Kadastik Ü, Karro H, Laisk T, Salumets A, Matt K, Peters M. 
(2011) Endometrioos-anamneesist diagnoosini. Eesti Arst Eesti Arst, 90(7), 
321 –326. 
Laisk T, Peters M, Saare M, Haller-Kikkatalo K, Karro H, Salumets A. Asso-
ciation of CCR5, TLR2, TLR4 and MBL genetic variations with genital tract 
infections and tubal factor infertility. J Reprod Immunol 2010; 87:74–81. 
Lamp M, Saare M, Laisk T, Karro H, Kadastik U, Metspalu A, Peters M, 
Salumets A. Genetic variations in vascular endothelial growth factor but not 
in angiotensin I-converting enzyme genes are associated with endometriosis 
in Estonian women. Eur J Obstet Gynecol Reprod Biol 2010; 153:85–89. 
Peters M, Saare M, Kaart T, Haller-Kikkatalo K, Lend AK, Punab M, Metspalu A, 
Salumets A. Analysis of polymorphisms in the SRD5A2 gene and semen 
parameters in Estonian men. J Androl 2010; 31:372–378. 
Saare M, Lamp M, Kaart T, Karro H, Kadastik U, Metspalu A, Peters M, 
Salumets A. Polymorphisms in MMP-2 and MMP-9 promoter regions are 
associated with endometriosis. Fertil Steril 2010; 94:1560–1563. 
Altmae S, Haller K, Peters M, Saare M, Hovatta O, Stavreus-Evers A, Velthut A, 
Karro H, Metspalu A, Salumets A. Aromatase gene (CYP19A1) variants, 
female infertility and ovarian stimulation outcome: a preliminary report. 
Reprod Biomed Online 2009; 18:651–657. 
Saare M, Belousova A, Punab M, Peters M, Haller K, Ausmees K, Poola-
mets O, Karro H, Metspalu A, Salumets A. Androgen receptor gene haplo-
type is associated with male infertility. Int J Androl 2008; 31:395–402. 
11  3
Saare M, Lend A.K, Sikut A, Salumets A, Peters M. (2008). Mehe geneetiline 
viljatus. Eesti Arst, 628–634. 
Altmäe S, Haller K, Saare M, Peters M, Karro H, Metspalu A, Salumets A. 
(2007). Aromataasi CYP19 geeni (TTTA)n variatsioon mõjutab FSH-
stimulatsiooni tulemuslikkust lastetuse ravis. Eesti Arst, 86(9), 685–686. 
Laasik E, Ojarand M, Pajunen M, Savilahti H, Mae A. Novel mutants of 
Erwinia carotovora subsp. carotovora defective in the production of plant 
cell wall degrading enzymes generated by Mu transpososome-mediated 
insertion mutagenesis. FEMS Microbiol Lett 2005; 243:93–99 
5 
114 
ELULOOKIRJELDUS 
Nimi:  Merli Saare 
Sünniaeg:  28.11.1976 
Kodakondsus:  eestlane 
Telefon:  +372 7330402 
E-mail:  merli.saare@ut.ee 
 
Haridustee:  
2011–...  Tartu Ülikool doktoriõpingud arstiteadustes 
2005–2008  Tartu Ülikool, arstiteaduskond, biomeditsiini magistriõpe 
2001–2005  Tartu Ülikool, bioloogia-geograafiateaduskond, geenitehno-
loogia eriala 
1993–1995  Hugo Treffneri Gümnaasium 
 
Teenistuskäik: 
2010–...  Tervisetehnoloogiate Arenduskeskus, teadur  
2009–... Tartu Ülikool, Kliinilise meditsiini instituut, naistekliinik, re-
produktiivmeditsiini teadur 
2008–2009  Eesti Biokeskus; teadur  
2008  Tartu Ülikool, Molekulaar- ja rakubioloogia instituut; teadur  
 
Õppetöö: 
Juhendamine: Kadri Madissoo, magistritöö biomeditsiini erialal, Tartu Ülikool, 
2012, (juh) Merli Saare; Andres Salumets; Neeme Tõnisson, “DNA koopiaarvu 
variatsioonid endometrioosiga naistel”. 
 
Publikatsioonid: 
Krjutskov K, Katayama S, Saare M, Vera-Rodriguez M, Lubenets D, Samuel K, 
Laisk-Podar T, Teder H, Einarsdottir E, Salumets A, Kere J. Single-cell 
transcriptome analysis of endometrial tissue. Hum Reprod 2016. 
Saare M, Modhukur V, Suhorutshenko M, Rajashekar B, Rekker K, Soritsa D, 
Karro H, Soplepmann P, Soritsa A, Lindgren CM, Rahmioglu N, Drong A, 
Becker CM, Zondervan KT, Salumets A, Peters M. The influence of 
menstrual cycle and endometriosis on endometrial methylome. Clin 
Epigenetics 2016; 8:2. 
Rekker K, Saare M, Roost AM, Kaart T, Soritsa D, Karro H, Soritsa A, Simon C, 
Salumets A, Peters M. Circulating miR-200-family micro-RNAs have altered 
plasma levels in patients with endometriosis and vary with blood collection 
time. Fertil Steril 2015; 104:938–946 e932. 
Soritsa D, Saare M, Laisk-Podar T, Peters M, Soritsa A, Matt K, Karro H, 
Salumets A. Pregnancy rate in endometriosis patients according to the 
severity of the disease after using a combined approach of laparoscopy, 
GnRH agonist treatment and in vitro fertilization. Gynecol Obstet Invest 
2015; 79:34–39 
115 
Saare M, Rekker K, Laisk-Podar T, Soritsa D, Roost AM, Simm J, Velthut-
Meikas A, Samuel K, Metsalu T, Karro H, Soritsa A, Salumets A, Peters M. 
High-Throughput Sequencing Approach Uncovers the miRNome of 
Peritoneal Endometriotic Lesions and Adjacent Healthy Tissues. PLoS One 
2014; 9:e112630. 
Rekker K, Saare M, Roost AM, Kubo AL, Zarovni N, Chiesi A, Salumets A, 
Peters M. Comparison of serum exosome isolation methods for microRNA 
profiling. Clin Biochem 2014; 47:135–138. 
Rekker K, Saare M, Roost AM, Salumets A, Peters M. Circulating microRNA 
Profile throughout the menstrual cycle. PLoS One 2013; 8:e81166. 
Altmae S, Reimand J, Hovatta O, Zhang P, Kere J, Laisk T, Saare M, Peters M, 
Vilo J, Stavreus-Evers A, Salumets A. Research resource: interactome of 
human embryo implantation: identification of gene expression pathways, 
regulation, and integrated regulatory networks. Mol Endocrinol 2012; 
26:203–217. 
Lamp M, Saare M, Kadastik U, Karro H, Salumets A, Uibo R, Peters M. 
Survivin promoter polymorphisms and autoantibodies in endometriosis. J 
Reprod Immunol 2012; 96:95–100. 
Saare M, Soritsa D, Vaidla K, Palta P, Remm M, Laan M, Karro H, Soritsa A, 
Salumets A, D’Hooghe T, Peters M. No evidence of somatic DNA copy 
number alterations in eutopic and ectopic endometrial tissue in 
endometriosis. Hum Reprod 2012; 27:1857–1864. 
Saare M, Lamp M, Kadastik Ü, Karro H, Laisk T, Salumets A, Matt K, Peters 
M. (2011) Endometrioos-anamneesist diagnoosini. Eesti Arst Eesti Arst, 
90(7), 321–326. 
Laisk T, Peters M, Saare M, Haller-Kikkatalo K, Karro H, Salumets A. 
Association of CCR5, TLR2, TLR4 and MBL genetic variations with genital 
tract infections and tubal factor infertility. J Reprod Immunol 2010; 87:74–
81. 
Lamp M, Saare M, Laisk T, Karro H, Kadastik U, Metspalu A, Peters M, 
Salumets A. Genetic variations in vascular endothelial growth factor but not 
in angiotensin I-converting enzyme genes are associated with endometriosis 
in Estonian women. Eur J Obstet Gynecol Reprod Biol 2010; 153:85–89. 
Peters M, Saare M, Kaart T, Haller-Kikkatalo K, Lend AK, Punab M, Metspalu 
A, Salumets A. Analysis of polymorphisms in the SRD5A2 gene and semen 
parameters in Estonian men. J Androl 2010; 31:372–378. 
Saare M, Lamp M, Kaart T, Karro H, Kadastik U, Metspalu A, Peters M, 
Salumets A. Polymorphisms in MMP-2 and MMP-9 promoter regions are 
associated with endometriosis. Fertil Steril 2010; 94:1560–1563. 
Altmae S, Haller K, Peters M, Saare M, Hovatta O, Stavreus-Evers A, Velthut 
A, Karro H, Metspalu A, Salumets A. Aromatase gene (CYP19A1) variants, 
female infertility and ovarian stimulation outcome: a preliminary report. 
Reprod Biomed Online 2009; 18:651–657. 
116 
Saare M, Belousova A, Punab M, Peters M, Haller K, Ausmees K, Poolamets O, 
Karro H, Metspalu A, Salumets A. Androgen receptor gene haplotype is 
associated with male infertility. Int J Androl 2008; 31:395–402. 
Saare M, Lend A.K, Sikut A, Salumets A, Peters M. (2008). Mehe geneetiline 
viljatus. Eesti Arst, 628–634. 
Altmäe S, Haller K, Saare M, Peters M, Karro H, Metspalu A, Salumets A. 
(2007). Aromataasi CYP19 geeni (TTTA)n variatsioon mõjutab FSH-
stimulatsiooni tulemuslikkust lastetuse ravis. Eesti Arst, 86(9), 685–686. 
Laasik E, Ojarand M, Pajunen M, Savilahti H, Mae A. Novel mutants of 
Erwinia carotovora subsp. carotovora defective in the production of plant 
cell wall degrading enzymes generated by Mu transpososome-mediated 
insertion mutagenesis. FEMS Microbiol Lett 2005; 243:93–99 
 
117 
DISSERTATIONES MEDICINAE  
UNIVERSITATIS TARTUENSIS 
 
 1. Heidi-Ingrid Maaroos. The natural course of gastric ulcer in connection 
with chronic gastritis and Helicobacter pylori. Tartu, 1991. 
 2. Mihkel Zilmer. Na-pump in normal and tumorous brain tissues: Structu-
ral, functional and tumorigenesis aspects. Tartu, 1991. 
 3. Eero Vasar. Role of cholecystokinin receptors in the regulation of beha-
viour and in the action of haloperidol and diazepam. Tartu, 1992. 
 4. Tiina Talvik. Hypoxic-ischaemic brain damage in neonates (clinical, 
biochemical and brain computed tomographical investigation). Tartu, 1992. 
 5. Ants Peetsalu. Vagotomy in duodenal ulcer disease: A study of gastric 
acidity, serum pepsinogen I, gastric mucosal histology and Helicobacter 
pylori. Tartu, 1992. 
 6. Marika Mikelsaar. Evaluation of the gastrointestinal microbial ecosystem 
in health and disease. Tartu, 1992. 
 7. Hele Everaus. Immuno-hormonal interactions in chronic lymphocytic leu-
kaemia and multiple myeloma. Tartu, 1993. 
 8. Ruth Mikelsaar. Etiological factors of diseases in genetically consulted 
children and newborn screening: dissertation for the commencement of the 
degree of doctor of medical sciences. Tartu, 1993. 
 9. Agu Tamm. On metabolic action of intestinal microflora: clinical aspects. 
Tartu, 1993. 
 10. Katrin Gross. Multiple sclerosis in South-Estonia (epidemiological and 
computed tomographical investigations). Tartu, 1993. 
 11. Oivi Uibo. Childhood coeliac disease in Estonia: occurrence, screening, 
diagnosis and clinical characterization. Tartu, 1994. 
 12. Viiu Tuulik. The functional disorders of central nervous system of che-
mistry workers. Tartu, 1994. 
 13. Margus Viigimaa. Primary haemostasis, antiaggregative and anticoagulant 
treatment of acute myocardial infarction. Tartu, 1994. 
 14. Rein Kolk. Atrial versus ventricular pacing in patients with sick sinus 
syndrome. Tartu, 1994. 
 15. Toomas Podar. Incidence of childhood onset type 1 diabetes mellitus in 
Estonia. Tartu, 1994. 
 16. Kiira Subi. The laboratory surveillance of the acute respiratory viral 
infections in Estonia. Tartu, 1995. 
17. Irja Lutsar. Infections of the central nervous system in children (epidemi-
ologic, diagnostic and therapeutic aspects, long term outcome). Tartu, 1995. 
18. Aavo Lang. The role of dopamine, 5-hydroxytryptamine, sigma and 
NMDA receptors in the action of antipsychotic drugs. Tartu, 1995. 
19.  Andrus Arak. Factors influencing the survival of patients after radical 
surgery for gastric cancer. Tartu, 1996. 
5 
118 
20.  Tõnis Karki. Quantitative composition of the human lactoflora and 
method for its examination. Tartu, 1996. 
21. Reet Mändar. Vaginal microflora during pregnancy and its transmission 
to newborn. Tartu, 1996.  
22. Triin Remmel. Primary biliary cirrhosis in Estonia: epidemiology, clinical 
characterization and prognostication of the course of the disease. Tartu, 
1996. 
23. Toomas Kivastik. Mechanisms of drug addiction: focus on positive rein-
forcing properties of morphine. Tartu, 1996.  
24.  Paavo Pokk. Stress due to sleep deprivation: focus on GABAA receptor-
chloride ionophore complex. Tartu, 1996. 
25. Kristina Allikmets. Renin system activity in essential hypertension. As-
sociations with atherothrombogenic cardiovascular risk factors and with 
the efficacy of calcium antagonist treatment. Tartu, 1996. 
26. Triin Parik. Oxidative stress in essential hypertension: Associations with 
metabolic disturbances and the effects of calcium antagonist treatment. 
Tartu, 1996. 
27.  Svetlana Päi. Factors promoting heterogeneity of the course of rheumatoid 
arthritis. Tartu, 1997.  
28. Maarike Sallo. Studies on habitual physical activity and aerobic fitness in 
4 to 10 years old children. Tartu, 1997. 
29. Paul Naaber. Clostridium difficile infection and intestinal microbial eco-
logy. Tartu, 1997. 
30. Rein Pähkla. Studies in pinoline pharmacology. Tartu, 1997. 
31. Andrus Juhan Voitk. Outpatient laparoscopic cholecystectomy. Tartu, 1997. 
32. Joel Starkopf. Oxidative stress and ischaemia-reperfusion of the heart. 
Tartu, 1997. 
33.  Janika Kõrv. Incidence, case-fatality and outcome of stroke. Tartu, 1998. 
34. Ülla Linnamägi. Changes in local cerebral blood flow and lipid peroxida-
tion following lead exposure in experiment. Tartu, 1998. 
35. Ave Minajeva. Sarcoplasmic reticulum function: comparison of atrial and 
ventricular myocardium. Tartu, 1998. 
36. Oleg Milenin. Reconstruction of cervical part of esophagus by revascular-
ised ileal autografts in dogs. A new complex multistage method. Tartu, 
1998. 
37. Sergei Pakriev. Prevalence of depression, harmful use of alcohol and 
alcohol dependence among rural population in Udmurtia. Tartu, 1998. 
38. Allen Kaasik. Thyroid hormone control over β-adrenergic signalling 
system in rat atria. Tartu, 1998. 
39. Vallo Matto. Pharmacological studies on anxiogenic and antiaggressive 
properties of antidepressants. Tartu, 1998. 
40. Maire Vasar. Allergic diseases and bronchial hyperreactivity in Estonian 
children in relation to environmental influences. Tartu, 1998. 
41. Kaja Julge. Humoral immune responses to allergens in early childhood. 
Tartu, 1998. 
119 
42. Heli Grünberg. The cardiovascular risk of Estonian schoolchildren. 
A cross-sectional study of 9-, 12- and 15-year-old children. Tartu, 1998. 
43. Epp Sepp. Formation of intestinal microbial ecosystem in children. Tartu, 
1998. 
44. Mai Ots. Characteristics of the progression of human and experimental 
glomerulopathies. Tartu, 1998. 
45. Tiina Ristimäe. Heart rate variability in patients with coronary artery 
disease. Tartu, 1998. 
46. Leho Kõiv. Reaction of the sympatho-adrenal and hypothalamo-pituitary-
adrenocortical system in the acute stage of head injury. Tartu, 1998. 
47. Bela Adojaan. Immune and genetic factors of childhood onset IDDM in 
Estonia. An epidemiological study. Tartu, 1999. 
48. Jakov Shlik. Psychophysiological effects of cholecystokinin in humans. 
Tartu, 1999. 
49. Kai Kisand. Autoantibodies against dehydrogenases of α-ketoacids. Tartu, 
1999. 
50. Toomas Marandi. Drug treatment of depression in Estonia. Tartu, 1999. 
51. Ants Kask. Behavioural studies on neuropeptide Y. Tartu, 1999. 
52. Ello-Rahel Karelson. Modulation of adenylate cyclase activity in the rat 
hippocampus by neuropeptide galanin and its chimeric analogs. Tartu, 1999. 
53. Tanel Laisaar. Treatment of pleural empyema — special reference to 
intrapleural therapy with streptokinase and surgical treatment modalities. 
Tartu, 1999. 
54. Eve Pihl. Cardiovascular risk factors in middle-aged former athletes. 
Tartu, 1999. 
55.  Katrin Õunap. Phenylketonuria in Estonia: incidence, newborn screening, 
diagnosis, clinical characterization and genotype/phenotype correlation. 
Tartu, 1999. 
56. Siiri Kõljalg. Acinetobacter – an important nosocomial pathogen. Tartu, 
1999. 
57. Helle Karro. Reproductive health and pregnancy outcome in Estonia: 
association with different factors. Tartu, 1999. 
58. Heili Varendi. Behavioral effects observed in human newborns during 
exposure to naturally occurring odors. Tartu, 1999.  
59. Anneli Beilmann. Epidemiology of epilepsy in children and adolescents in 
Estonia. Prevalence, incidence, and clinical characteristics. Tartu, 1999. 
60. Vallo Volke. Pharmacological and biochemical studies on nitric oxide in 
the regulation of behaviour. Tartu, 1999. 
61.  Pilvi Ilves. Hypoxic-ischaemic encephalopathy in asphyxiated term infants. 
A prospective clinical, biochemical, ultrasonographical study. Tartu, 1999. 
62. Anti Kalda. Oxygen-glucose deprivation-induced neuronal death and its 
pharmacological prevention in cerebellar granule cells. Tartu, 1999. 
63.  Eve-Irene Lepist. Oral peptide prodrugs – studies on stability and 
absorption. Tartu, 2000. 
120 
64. Jana Kivastik. Lung function in Estonian schoolchildren: relationship 
with anthropometric indices and respiratory symptomas, reference values 
for dynamic spirometry. Tartu, 2000. 
65. Karin Kull. Inflammatory bowel disease: an immunogenetic study. Tartu, 
2000. 
66. Kaire Innos. Epidemiological resources in Estonia: data sources, their 
quality and feasibility of cohort studies. Tartu, 2000. 
67. Tamara Vorobjova. Immune response to Helicobacter pylori and its 
association with dynamics of chronic gastritis and epithelial cell turnover 
in antrum and corpus. Tartu, 2001. 
68. Ruth Kalda. Structure and outcome of family practice quality in the 
changing health care system of Estonia. Tartu, 2001. 
69. Annika Krüüner. Mycobacterium tuberculosis – spread and drug 
resistance in Estonia. Tartu, 2001. 
70. Marlit Veldi. Obstructive Sleep Apnoea: Computerized Endopharyngeal 
Myotonometry of the Soft Palate and Lingual Musculature. Tartu, 2001. 
71. Anneli Uusküla. Epidemiology of sexually transmitted diseases in Estonia 
in 1990–2000. Tartu, 2001. 
72. Ade Kallas. Characterization of antibodies to coagulation factor VIII. 
Tartu, 2002. 
73. Heidi Annuk. Selection of medicinal plants and intestinal lactobacilli as 
antimicrobil components for functional foods. Tartu, 2002.  
74. Aet Lukmann. Early rehabilitation of patients with ischaemic heart 
disease after surgical revascularization of the myocardium:  assessment of 
health-related quality of life, cardiopulmonary reserve and oxidative stress. 
A clinical study. Tartu, 2002. 
75. Maigi Eisen. Pathogenesis of Contact Dermatitis: participation of Oxida-
tive Stress. A clinical – biochemical study. Tartu, 2002. 
76. Piret Hussar. Histology of the post-traumatic bone repair in rats. Elabora-
tion and use of a new standardized experimental model – bicortical perfora-
tion of tibia compared to internal fracture and resection osteotomy. Tartu, 
2002. 
77. Tõnu Rätsep. Aneurysmal subarachnoid haemorrhage: Noninvasive moni-
toring of cerebral haemodynamics. Tartu, 2002. 
78. Marju Herodes. Quality of life of people with epilepsy in Estonia. Tartu, 
2003. 
79. Katre Maasalu. Changes in bone quality due to age and genetic disorders 
and their clinical expressions in Estonia. Tartu, 2003. 
80. Toomas Sillakivi. Perforated peptic ulcer in Estonia: epidemiology, risk 
factors and relations with Helicobacter pylori. Tartu, 2003. 
81. Leena Puksa. Late responses in motor nerve conduction studies. F and A 
waves in normal subjects and patients with neuropathies. Tartu, 2003. 
82. Krista Lõivukene. Helicobacter pylori in gastric microbial ecology and  
its antimicrobial susceptibility pattern. Tartu, 2003. 
83. Helgi Kolk. Dyspepsia and Helicobacter pylori infection: the diagnostic 
value of symptoms, treatment and follow-up of patients referred for upper 
gastrointestinal endoscopy by family physicians. Tartu, 2003. 
84. Helena Soomer. Validation of identification and age estimation methods 
in forensic odontology. Tartu, 2003. 
85. Kersti Oselin. Studies on the human MDR1, MRP1, and MRP2 ABC 
transporters: functional relevance of the genetic polymorphisms in the 
MDR1 and MRP1 gene. Tartu, 2003. 
86. Jaan Soplepmann. Peptic ulcer haemorrhage in Estonia: epidemiology, 
prognostic factors, treatment and outcome. Tartu, 2003. 
87. Margot Peetsalu. Long-term follow-up after vagotomy in duodenal ulcer 
disease: recurrent ulcer, changes in the function, morphology and Helico-
bacter pylori colonisation of the gastric mucosa. Tartu, 2003. 
88. Kersti Klaamas. Humoral immune response to Helicobacter pylori a study 
of host-dependent and microbial factors. Tartu, 2003. 
89. Pille Taba. Epidemiology of Parkinson’s disease in Tartu, Estonia. Pre-
valence, incidence, clinical characteristics, and pharmacoepidemiology. 
Tartu, 2003.  
90. Alar Veraksitš. Characterization of behavioural and biochemical pheno-
type of cholecystokinin-2 receptor deficient mice: changes in the function 
of the dopamine and endopioidergic system. Tartu, 2003. 
91. Ingrid Kalev. CC-chemokine receptor 5 (CCR5) gene polymorphism in 
Estonians and in patients with Type I and Type II diabetes mellitus. Tartu, 
2003. 
92. Lumme Kadaja. Molecular approach to the regulation of mitochondrial 
function in oxidative muscle cells. Tartu, 2003. 
93. Aive Liigant. Epidemiology of primary central nervous system tumours in 
Estonia from 1986 to 1996. Clinical characteristics, incidence, survival and 
prognostic factors. Tartu, 2004. 
94. Andres, Kulla. Molecular characteristics of mesenchymal stroma in 
human astrocytic gliomas. Tartu, 2004. 
95. Mari Järvelaid. Health damaging risk behaviours in adolescence. Tartu, 
2004. 
96. Ülle Pechter. Progression prevention strategies in chronic renal failure and 
hypertension. An experimental and clinical study. Tartu, 2004. 
97. Gunnar Tasa. Polymorphic glutathione S-transferases – biology and role 
in modifying genetic susceptibility to senile cataract and primary open 
angle glaucoma. Tartu, 2004. 
98. Tuuli Käämbre. Intracellular energetic unit: structural and functional 
aspects. Tartu, 2004. 
99.  Vitali Vassiljev. Influence of nitric oxide syntase inhibitors on the effects  
of ethanol after acute and chronic ethanol administration and withdrawal. 
Tartu, 2004. 
121 5 
122 
100. Aune Rehema. Assessment of nonhaem ferrous iron and glutathione 
redox ratio as markers of pathogeneticity of oxidative stress in different 
clinical groups. Tartu, 2004. 
101.   Evelin Seppet. Interaction of mitochondria and ATPases in oxidative 
muscle cells in normal and pathological conditions. Tartu, 2004. 
102. Eduard Maron. Serotonin function in panic disorder: from clinical expe-
riments to brain imaging and genetics. Tartu, 2004.  
103. Marje Oona. Helicobacter pylori infection in children: epidemiological 
and therapeutic aspects. Tartu, 2004. 
104. Kersti Kokk. Regulation of active and passive molecular transport in the 
testis. Tartu, 2005.  
105. Vladimir Järv. Cross-sectional imaging for pretreatment evaluation and 
follow-up of pelvic malignant tumours. Tartu, 2005. 
106. Andre Õun. Epidemiology of adult epilepsy in Tartu, Estonia. Incidence, 
prevalence and medical treatment. Tartu, 2005. 
107. Piibe Muda. Homocysteine and hypertension: associations between 
homocysteine and essential hypertension in treated and untreated hyper-
tensive patients with and without coronary artery disease. Tartu, 2005. 
108. Külli Kingo. The interleukin-10 family cytokines gene polymorphisms in 
plaque psoriasis. Tartu, 2005.  
109. Mati Merila. Anatomy and clinical relevance of the glenohumeral joint  
capsule and ligaments. Tartu, 2005. 
110. Epp Songisepp. Evaluation of technological and functional properties of 
the new probiotic Lactobacillus fermentum ME-3. Tartu, 2005. 
111. Tiia Ainla. Acute myocardial infarction in Estonia: clinical characte-
ristics, management and outcome. Tartu, 2005. 
112. Andres Sell. Determining the minimum local anaesthetic requirements for 
hip replacement surgery under spinal anaesthesia – a study employing a 
spinal catheter. Tartu, 2005. 
113. Tiia Tamme. Epidemiology of odontogenic tumours in Estonia. Patho-
genesis and clinical behaviour of ameloblastoma. Tartu, 2005. 
114. Triine Annus. Allergy in Estonian schoolchildren: time trends and 
characteristics. Tartu, 2005. 
115. Tiia Voor. Microorganisms in infancy and development of allergy: com-
parison  of  Estonian  and Swedish  children. Tartu, 2005. 
116. Priit Kasenõmm. Indicators for tonsillectomy in adults with recurrent 
tonsillitis – clinical, microbiological and pathomorphological investi-
gations. Tartu, 2005. 
117. Eva Zusinaite. Hepatitis C virus: genotype identification and interactions 
between viral proteases. Tartu, 2005. 
118. Piret Kõll. Oral lactoflora in chronic periodontitis and periodontal health. 
Tartu, 2006. 
119. Tiina Stelmach. Epidemiology of cerebral palsy and unfavourable neuro-
developmental outcome in child population of Tartu city and county, 
Estonia Prevalence, clinical features and risk factors. Tartu, 2006. 
123 
120. Katrin Pudersell. Tropane alkaloid production and riboflavine excretion 
in the field and tissue cultures of henbane (Hyoscyamus niger L.). Tartu, 
2006.  
121. Külli Jaako. Studies on the role of neurogenesis in brain plasticity. Tartu, 
2006.  
122. Aare Märtson. Lower limb lengthening: experimental studies of bone 
regeneration and long-term clinical results. Tartu, 2006. 
123.  Heli Tähepõld. Patient consultation in family medicine. Tartu, 2006. 
124. Stanislav Liskmann. Peri-implant disease: pathogenesis, diagnosis and 
treatment in view of both inflammation and oxidative stress profiling. 
Tartu, 2006. 
125. Ruth Rudissaar. Neuropharmacology of atypical antipsychotics and an 
animal model of psychosis. Tartu, 2006. 
126. Helena Andreson. Diversity of Helicobacter pylori genotypes in 
Estonian patients with chronic inflammatory gastric diseases. Tartu, 2006. 
127. Katrin Pruus. Mechanism of action of antidepressants: aspects of sero-
toninergic system and its interaction with glutamate. Tartu, 2006. 
128. Priit Põder. Clinical and experimental investigation: relationship of 
ischaemia/reperfusion injury with oxidative stress in abdominal aortic 
aneurysm repair and in extracranial brain artery endarterectomy and possi-
bilities of protection against ischaemia using a glutathione analogue in a 
rat model of global brain ischaemia. Tartu, 2006.   
129. Marika Tammaru. Patient-reported outcome measurement in rheumatoid 
arthritis. Tartu, 2006. 
130.   Tiia Reimand. Down syndrome in Estonia. Tartu, 2006. 
131. Diva Eensoo. Risk-taking in traffic and Markers of Risk-Taking Beha-
viour in Schoolchildren and Car Drivers. Tartu, 2007. 
132. Riina Vibo. The third stroke registry in Tartu, Estonia from 2001 to 2003: 
incidence, case-fatality, risk factors and long-term outcome. Tartu, 2007.  
133. Chris Pruunsild. Juvenile idiopathic arthritis in children in Estonia. 
Tartu, 2007. 
134. Eve Õiglane-Šlik. Angelman and Prader-Willi syndromes in Estonia. 
Tartu, 2007. 
135. Kadri Haller. Antibodies to follicle stimulating hormone. Significance in 
female infertility. Tartu, 2007. 
136.  Pille Ööpik. Management of depression in family medicine. Tartu, 2007. 
137. Jaak Kals. Endothelial function and arterial stiffness in patients with 
atherosclerosis and in healthy subjects. Tartu, 2007. 
138.  Priit Kampus. Impact of inflammation, oxidative stress and age on 
arterial stiffness and carotid artery intima-media thickness. Tartu, 2007. 
139.  Margus Punab. Male fertility and its risk factors in Estonia. Tartu, 2007. 
140. Alar Toom. Heterotopic ossification after total hip arthroplasty: clinical 
and pathogenetic investigation. Tartu, 2007. 
124 
141. Lea Pehme. Epidemiology of tuberculosis in Estonia 1991–2003 with 
special regard to extrapulmonary tuberculosis and delay in diagnosis of 
pulmonary tuberculosis. Tartu, 2007. 
142.  Juri Karjagin. The pharmacokinetics of metronidazole and meropenem 
in septic shock. Tartu, 2007. 
143. Inga Talvik. Inflicted traumatic brain injury shaken baby syndrome in 
Estonia – epidemiology and outcome. Tartu, 2007. 
144.  Tarvo Rajasalu. Autoimmune diabetes: an immunological study of type 
1 diabetes in humans and in a model of experimental diabetes (in RIP-
B7.1 mice). Tartu, 2007. 
145. Inga Karu. Ischaemia-reperfusion injury of the heart during coronary 
surgery: a clinical study investigating the effect of hyperoxia. Tartu, 2007. 
146. Peeter Padrik. Renal cell carcinoma: Changes in natural history and 
treatment of metastatic disease. Tartu, 2007.  
147.  Neve Vendt. Iron deficiency and iron deficiency anaemia in infants aged 
9 to 12 months in Estonia. Tartu, 2008.  
148. Lenne-Triin Heidmets. The effects of neurotoxins on brain plasticity: 
focus on neural Cell Adhesion Molecule. Tartu, 2008. 
149.  Paul Korrovits. Asymptomatic inflammatory prostatitis: prevalence, etio-
logical factors, diagnostic tools. Tartu, 2008. 
150.   Annika Reintam. Gastrointestinal failure in intensive care patients. Tartu, 
2008. 
151.   Kristiina Roots. Cationic regulation of Na-pump in the normal, Alzhei-
mer’s and CCK2 receptor-deficient brain. Tartu, 2008. 
152. Helen Puusepp. The genetic causes of mental retardation in Estonia: 
fragile X syndrome and creatine transporter defect. Tartu, 2009. 
153. Kristiina Rull. Human chorionic gonadotropin beta genes and recurrent 
miscarriage: expression and variation study. Tartu, 2009. 
154.  Margus Eimre. Organization of energy transfer and feedback regulation 
in oxidative muscle cells. Tartu, 2009. 
155. Maire Link. Transcription factors FoxP3 and AIRE: autoantibody 
associations. Tartu, 2009. 
156.  Kai Haldre. Sexual health and behaviour of young women in Estonia. 
Tartu, 2009. 
157. Kaur Liivak. Classical form of congenital adrenal hyperplasia due to  
21-hydroxylase deficiency in Estonia: incidence, genotype and phenotype 
with special attention to short-term growth and 24-hour blood pressure. 
Tartu, 2009. 
158. Kersti Ehrlich. Antioxidative glutathione analogues (UPF peptides) – 
molecular design, structure-activity relationships and testing the protec-
tive properties. Tartu, 2009. 
159. Anneli Rätsep. Type 2 diabetes care in family medicine. Tartu, 2009. 
160. Silver Türk. Etiopathogenetic aspects of chronic prostatitis: role of 
mycoplasmas, coryneform bacteria and oxidative stress. Tartu, 2009. 
125 
161. Kaire Heilman. Risk markers for cardiovascular disease and low bone 
mineral density in children with type 1 diabetes. Tartu, 2009. 
162.  Kristi Rüütel. HIV-epidemic in Estonia: injecting drug use and quality of 
life of people living with HIV. Tartu, 2009. 
163. Triin Eller. Immune markers in major depression and in antidepressive 
treatment. Tartu, 2009. 
164.  Siim Suutre. The role of TGF-β isoforms and osteoprogenitor cells in the 
pathogenesis of heterotopic ossification. An experimental and clinical 
study of hip arthroplasty. Tartu, 2010. 
165.  Kai Kliiman. Highly drug-resistant tuberculosis in Estonia: Risk factors 
and predictors of poor treatment outcome. Tartu, 2010.  
166.  Inga Villa. Cardiovascular health-related nutrition, physical activity and 
fitness in Estonia. Tartu, 2010. 
167. Tõnis Org. Molecular function of the first PHD finger domain of Auto-
immune Regulator protein. Tartu, 2010.  
168. Tuuli Metsvaht. Optimal antibacterial therapy of neonates at risk of early 
onset sepsis. Tartu, 2010. 
169.  Jaanus Kahu. Kidney transplantation: Studies on donor risk factors and 
mycophenolate mofetil. Tartu, 2010.  
170.  Koit Reimand. Autoimmunity in reproductive failure: A study on as-
sociated autoantibodies and autoantigens. Tartu, 2010. 
171. Mart Kull. Impact of vitamin D and hypolactasia on bone mineral 
density: a population based study in Estonia. Tartu, 2010. 
172. Rael Laugesaar. Stroke in children – epidemiology and risk factors. 
Tartu, 2010.  
173.  Mark Braschinsky. Epidemiology and quality of life issues of hereditary 
spastic paraplegia in Estonia and implemention of genetic analysis in 
everyday neurologic practice. Tartu, 2010. 
174. Kadri Suija. Major depression in family medicine: associated factors, 
recurrence and possible intervention. Tartu, 2010. 
175. Jarno Habicht. Health care utilisation in Estonia: socioeconomic determi-
nants and financial burden of out-of-pocket payments. Tartu, 2010. 
176. Kristi Abram. The prevalence and risk factors of rosacea. Subjective 
disease perception of rosacea patients. Tartu, 2010. 
177. Malle Kuum. Mitochondrial and endoplasmic reticulum cation fluxes: 
Novel roles in cellular physiology. Tartu, 2010. 
178. Rita Teek. The genetic causes of early onset hearing loss in Estonian 
children. Tartu, 2010. 
179. Daisy Volmer. The development of community pharmacy services in 
Estonia – public and professional perceptions 1993–2006. Tartu, 2010. 
180. Jelena Lissitsina. Cytogenetic causes in male infertility. Tartu, 2011. 
181.  Delia Lepik. Comparison of gunshot injuries caused from Tokarev, 
Makarov and Glock 19 pistols at different firing distances. Tartu, 2011. 
182.  Ene-Renate Pähkla. Factors related to the efficiency of treatment of 
advanced periodontitis. Tartu, 2011.  
5 
126 
183. Maarja Krass. L-Arginine pathways and antidepressant action. Tartu, 
2011.  
184.  Taavi Lai. Population health measures to support evidence-based  
health policy in Estonia. Tartu, 2011.  
185. Tiit Salum. Similarity and difference of temperature-dependence of the 
brain sodium pump in normal, different neuropathological, and aberrant 
conditions and its possible reasons. Tartu, 2011.  
186.  Tõnu Vooder. Molecular differences and similarities between histo-
logical subtypes of non-small cell lung cancer. Tartu, 2011.  
187.  Jelena Štšepetova. The characterisation of intestinal lactic acid bacteria 
using bacteriological, biochemical and molecular approaches. Tartu, 2011.  
188. Radko Avi. Natural polymorphisms and transmitted drug resistance in 
Estonian HIV-1 CRF06_cpx and its recombinant viruses. Tartu, 2011, 116 p. 
189.  Edward Laane. Multiparameter flow cytometry in haematological malig-
nancies. Tartu, 2011, 152 p. 
190.  Triin Jagomägi. A study of the genetic etiology of nonsyndromic cleft lip 
and palate. Tartu, 2011, 158 p. 
191.  Ivo Laidmäe. Fibrin glue of fish (Salmo salar) origin: immunological 
study and development of new pharmaceutical preparation. Tartu, 2012, 
150 p. 
192.  Ülle Parm. Early mucosal colonisation and its role in prediction of inva-
sive infection in neonates at risk of early onset sepsis. Tartu, 2012, 168 p. 
193.  Kaupo Teesalu. Autoantibodies against desmin and transglutaminase 2 in 
celiac disease: diagnostic and functional significance. Tartu, 2012, 142 p. 
194. Maksim Zagura. Biochemical, functional and structural profiling of 
arterial damage in atherosclerosis. Tartu, 2012, 162 p. 
195. Vivian Kont. Autoimmune regulator: characterization of thymic gene 
regulation and promoter methylation. Tartu, 2012, 134 p. 
196. Pirje Hütt. Functional properties, persistence, safety and efficacy of 
potential probiotic lactobacilli. Tartu, 2012, 246 p. 
197.  Innar Tõru. Serotonergic modulation of CCK-4- induced panic. Tartu, 
2012, 132 p. 
198.  Sigrid Vorobjov. Drug use, related risk behaviour and harm reduction 
interventions utilization among injecting drug users in Estonia: impli-
cations for drug policy. Tartu, 2012, 120 p. 
199.  Martin Serg. Therapeutic aspects of central haemodynamics, arterial 
stiffness and oxidative stress in hypertension. Tartu, 2012, 156 p.  
200. Jaanika Kumm. Molecular markers of articular tissues in early knee 
osteoarthritis: a population-based longitudinal study in middle-aged sub-
jects. Tartu, 2012, 159 p. 
201. Kertu Rünkorg. Functional changes of dopamine, endopioid and endo-
cannabinoid systems in CCK2 receptor deficient mice. Tartu, 2012, 125 p. 
202. Mai Blöndal. Changes in the baseline characteristics, management and 
outcomes of acute myocardial infarction in Estonia. Tartu, 2012, 127 p.        
127 
203. Jana Lass. Epidemiological and clinical aspects of medicines use in 
children in Estonia. Tartu, 2012, 170 p. 
204. Kai Truusalu. Probiotic lactobacilli in experimental persistent Salmo-
nella infection. Tartu, 2013, 139 p.  
205. Oksana Jagur.  Temporomandibular joint diagnostic imaging in relation 
to pain and bone characteristics. Long-term results of arthroscopic treat-
ment. Tartu, 2013, 126 p. 
206. Katrin Sikk. Manganese-ephedrone intoxication – pathogenesis of neuro-
logical damage and clinical symptomatology. Tartu, 2013, 125 p. 
207. Kai Blöndal. Tuberculosis in Estonia with special emphasis on drug-
resistant tuberculosis: Notification rate, disease recurrence and mortality. 
Tartu, 2013, 151 p. 
208. Marju Puurand. Oxidative phosphorylation in different diseases of 
gastric mucosa. Tartu, 2013, 123 p.  
209. Aili Tagoma. Immune activation in female infertility: Significance of 
autoantibodies and inflammatory mediators. Tartu, 2013, 135 p. 
210.  Liis Sabre. Epidemiology of traumatic spinal cord injury in Estonia. 
Brain activation in the acute phase of traumatic spinal cord injury. Tartu, 
2013, 135 p. 
211. Merit Lamp. Genetic susceptibility factors in endometriosis. Tartu, 2013, 
125 p. 
212.  Erik Salum. Beneficial effects of vitamin D and angiotensin II receptor 
blocker on arterial damage. Tartu, 2013, 167 p.   
213.  Maire Karelson. Vitiligo: clinical aspects, quality of life and the role of 
melanocortin system in pathogenesis. Tartu, 2013, 153 p.  
214. Kuldar Kaljurand. Prevalence of exfoliation syndrome in Estonia and its 
clinical significance. Tartu, 2013, 113 p.  
215.  Raido Paasma. Clinical study of methanol poisoning: handling large out-
breaks, treatment with antidotes, and long-term outcomes. Tartu, 2013,  
96 p. 
216.  Anne Kleinberg. Major depression in Estonia: prevalence, associated 
factors, and use of health services. Tartu, 2013, 129 p. 
217.  Triin Eglit. Obesity, impaired glucose regulation, metabolic syndrome 
and their associations with high-molecular-weight adiponectin levels. 
Tartu, 2014, 115 p. 
218.  Kristo Ausmees. Reproductive function in middle-aged males: Asso-
ciations with prostate, lifestyle and couple infertility status. Tartu, 2014, 
125 p.  
219.  Kristi Huik. The influence of host genetic factors on the susceptibility to 
HIV and HCV infections among intravenous drug users. Tartu, 2014, 
144 p.  
220. Liina Tserel. Epigenetic profiles of monocytes, monocyte-derived macro-
phages and dendritic cells. Tartu, 2014, 143 p. 
221. Irina Kerna. The contribution of ADAM12 and CILP genes to the 
development of knee osteoarthritis. Tartu, 2014, 152 p. 
128 
222. Ingrit Liiv. Autoimmune regulator protein interaction with DNA-depen-
dent protein kinase and its role in apoptosis. Tartu, 2014, 143 p. 
223.  Liivi Maddison. Tissue perfusion and metabolism during intra-abdominal 
hypertension. Tartu, 2014, 103 p. 
224.  Krista Ress. Childhood coeliac disease in Estonia, prevalence in atopic 
dermatitis and immunological characterisation of coexistence. Tartu, 
2014, 124 p. 
225.  Kai Muru. Prenatal screening strategies, long-term outcome of children 
with marked changes in maternal screening tests and the most common 
syndromic heart anomalies in Estonia. Tartu, 2014, 189 p. 
226. Kaja Rahu. Morbidity and mortality among Baltic Chernobyl cleanup 
workers: a register-based cohort study. Tartu, 2014, 155 p.  
227.  Klari Noormets. The development of diabetes mellitus, fertility and ener-
gy metabolism disturbances in a Wfs1-deficient mouse model of Wolfram 
syndrome. Tartu, 2014, 132 p. 
228. Liis Toome. Very low gestational age infants in Estonia. Tartu, 2014,  
183 p. 
229.  Ceith Nikkolo. Impact of different mesh parameters on chronic pain and 
foreign body feeling after open inguinal hernia repair. Tartu, 2014, 132 p. 
230.  Vadim Brjalin. Chronic hepatitis C: predictors of treatment response in 
Estonian patients. Tartu, 2014, 122 p. 
231.  Vahur Metsna. Anterior knee pain in patients following total knee arthro-
plasty: the prevalence, correlation with patellar cartilage impairment and 
aspects of patellofemoral congruence. Tartu, 2014, 130 p. 
232.  Marju Kase. Glioblastoma multiforme: possibilities to improve treatment 
efficacy. Tartu, 2015, 137 p.  
233. Riina Runnel. Oral health among elementary school children and the 
effects of polyol candies on the prevention of dental caries. Tartu, 2015, 
112 p. 
234. Made Laanpere. Factors influencing women’s sexual health and re-
productive choices in Estonia. Tartu, 2015, 176 p. 
235.  Andres Lust. Water mediated solid state transformations of a polymorphic 
drug – effect on pharmaceutical product performance. Tartu, 2015, 134 p.  
236. Anna Klugman. Functionality related characterization of pretreated wood 
lignin, cellulose and polyvinylpyrrolidone for pharmaceutical applications. 
Tartu, 2015, 156 p. 
237. Triin Laisk-Podar. Genetic variation as a modulator of susceptibility to 
female infertility and a source for potential biomarkers. Tartu, 2015, 155 p. 
238. Mailis Tõnisson. Clinical picture and biochemical changes in blood in 
children with acute alcohol intoxication. Tartu, 2015, 100 p. 
239. Kadri Tamme. High volume haemodiafiltration in treatment of severe 
sepsis – impact on pharmacokinetics of antibiotics and inflammatory 
response. Tartu, 2015, 133 p.  
 
 
240. Kai Part. Sexual health of young people in Estonia in a social context: the 
role of school-based sexuality education and youth-friendly counseling 
services. Tartu, 2015, 203 p. 
241. Urve Paaver. New perspectives for the amorphization and physical 
stabilization of poorly water-soluble drugs and understanding their 
dissolution behavior. Tartu, 2015, 139 p. 
242. Aleksandr Peet. Intrauterine and postnatal growth in children with HLA-
conferred susceptibility to type 1 diabetes. Tartu. 2015, 146 p. 
243. Piret Mitt. Healthcare-associated infections in Estonia – epidemiology 
and surveillance of bloodstream and surgical site infections. Tartu, 2015, 
145 p. 
5 
